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Abstract 
 
Alzheimer’s disease (AD) is the most common cause of dementia. Mild cognitive impairment 
(MCI) is a transitional state between normal ageing and dementia. Positron emission 
tomography (PET) can detect the metabolic and neuro-chemical changes that occur in MCI 
and dementia. The aim of this thesis was to assess the use of PET as an in vivo biomarker for 
early disease detection, prognosis, and proof of treatment efficacy in AD and MCI. 
In study I, the prevalence of increased beta-amyloid deposition (assessed by 11C-PIB PET) 
and microglial activation (assessed by 11C-PK11195 PET) was studied in amnestic MCI 
(aMCI) subjects. 50% had raised amyloid deposition and 38% evidence of microglial 
activation. Subjects with increased PIB retention had significantly higher cortical PK11195 
binding.  
In study II, rates at which aMCI subjects with and without increased amyloid load converted 
to AD were compared over one to three years of follow-up. 55% of aMCI subjects had 
significantly increased PIB retention at baseline and 82% of these converted to AD compared 
to 7% of aMCI cases with normal PIB uptake. Faster AD converters had higher PIB retention 
than slower converters.  
In study III, changes in regional cerebral Aβ deposition (assessed with 11C-PIB PET) and 
regional cerebral glucose metabolism (rCMRGlc) (assessed with 18F-FDG PET) were 
followed over three years in MCI and AD subjects. The MCI subjects demonstrated small but 
significant increases in 11C-PIB retention and parallel decreases in rCMRGlc. 11C-PIB 
retention in AD subjects remained unchanged, despite decreases in rCMRGlc and a decline in 
their MMSE.  
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In study IV, the effects of passive immunisation with infusions of the anti-Aβ monoclonal 
antibody bapineuzumab on amyloid plaque load was assessed in AD subjects. After 78 
weeks, subjects receiving bapineuzumab had reduced cortical 11C-PIB retention compared 
with their baseline and with placebo treated subjects.  
Through its detection of fibrillar Aβ, PET can detect the presence of Alzheimer pathology 
and provides a prognostic indicator of future progression of MCI to AD. However, PIB PET 
is not a marker of AD progression as the amyloid load remains relatively stable. 18F-FDG 
PET, a marker of synaptic activity, more closely mirrors cognitive decline as 
neurodegeneration progresses. Finally, PET allows the changes in glial activation in MCI to 
be monitored and provides a rationale for therapeutic trials of anti-inflammatory agents.  
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1. Introduction and Background 
 
1.1. Alzheimer’s disease (AD) 
In 1906 the German neuropathologist and psychiatrist Alois Alzheimer presented the case of 
a 51-year-old woman from Frankfurt to an audience of psychiatrists during his lecture in 
Tübingen, Germany. The woman was named Auguste D and she was admitted to a Frankfurt 
hospital in 1901 with progressive cognitive symptoms including memory impairment and 
difficulties with speech. Auguste D also exhibited unpredictable behaviour and was 
disorientated and showed symptoms of paranoia. During her life, she was diagnosed as 
having a pre-senile dementia and after her death in 1906 Alzheimer examined her brain. At 
the post-mortem examination, he found and described what are now considered to be the 
pathological hallmarks of AD; neurofibrillary tangles (NFTs) consisting of tau protein and 
senile plaques consisting of beta-amyloid (Aβ).  
 
1.1.1. Epidemiology 
Alzheimer’s disease (AD) is the most common cause of dementia, accounting for up to 60% 
of all cases. The estimated prevalence of AD is more than 20 million cases worldwide 
(Goedert and Spillantini 2006) and as the mean age of survival of the elderly population 
continues to increase, so too does the prevalence of AD, which is predicted to exceed 100 
million globally by the year 2050 (Brookmeyer et al. 2007). This increase in people affected 
with AD will place a significant economic and social burden on society as a whole, making 
both the early diagnosis of AD and the search for therapies that delay disease onset and slow 
disease progression a priority in the field of dementia research.  
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1.1.2. Aetiology 
1.1.2.1. Genetics  
1. Sporadic AD 
AD may be categorised as either sporadic or familial and can present either early (before the 
age of 65) or late. Sporadic AD is by far the most common form of AD accounting for more 
than 90% of cases, with the majority of these being late onset.  
The glycoprotein apolipoprotein e (APOE), encoded on chromosome 19, is a major lipid 
transporter within the brain. There are three common isoforms, APOE2, APOE3 and APOE4, 
encoded by three alleles ε2, ε3 and ε4 respectively. The allele ε4 of APOE is associated with 
both an increased risk of sporadic AD and an earlier age of onset (Gomez-Isla et al. 1996). 
This is a dosage effect, with ε4 homozygotes carrying a 90% risk of developing AD 
compared to only 20% in those with no ε4 allele. Similarly, the mean age of disease onset 
decreases from 84 to 68 years in those APOE ε4 homozygotes (Corder et al. 1993). The 
precise mechanism by which the ε4 allele confers this risk is still uncertain, although it is 
thought to play an Aβ dependent role in the pathogenesis of AD. In contrast, studies report 
the APOE ε2 allele to be associated with a lower risk of developing sporadic AD (Corder et 
al. 1993).    
2. Familial AD 
Familial AD is inherited in an autosomal dominant manner and accounts for only five percent 
of all AD cases (but 50% of early-onset AD cases). The most common cause of familial AD 
is mutations of the presenilin-1 (PSEN1) gene on chromosome 14. Mutations in the 
presenilin-2 (PSEN2) gene on chromosome 1, and the amyloid precursor protein (APP) gene 
on chromosome 21, account for the remainder of cases. To date, more than 180 mutations in 
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these genes have been described (http://www.molgen.ua.ac.be/ADMutations). Mutations in 
these genes facilitate the accumulation of Aβ 1-42, largely via altered APP processing.  
3. Further implicated genes 
Genome-wide association studies have recently identified and implicated three further 
susceptibility genetic loci for the development of late-onset AD. These are clusterin (CLU), 
phosphatidylinositol binding clarithin assembly protein (PICALM) and complement receptor 
1 (CR1) (Harold et al. 2009; Lambert et al. 2009). 
1.1.2.2. Other risk factors  
Several epidemiological studies (Skoog and Gustafson 2000; Breteler 2000) have reported 
other risk factors for AD, the most important of these being increasing age. Additional risk 
factors include a family history – especially maternal, hypertension, hypercholesterolaemia, 
diabetes, head injury and lower education. 
 
1.1.3. Anatomy and physiology of normal cognition and memory 
1.1.3.1. Cerebral cortex and subcortical structures  
The cerebral cortex is the outermost area of the brain and has extensive reciprocal 
connections with subcortical structures including the basal ganglia, the thalamus, the 
brainstem and cerebellum. Structurally, the cortex is divided into frontal, parietal, temporal 
and occipital lobes. Areas of the brain may be further subdivided on a functional level. Such 
areas include the primary motor and primary sensory cortices located within the frontal and 
parietal lobes respectively and the primary visual and auditory areas located within the 
occipital and temporal lobes.  
Areas of the brain that are involved in higher processing are known as association cortices. 
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These areas are found in the frontal, temporal and occipital lobes and include the parieto-
occipito-temporal, prefrontal and limbic association areas (Guyton 1991). The association 
areas receive and integrate information from a variety of sources including each other and the 
primary motor and sensory cortices, allowing complex tasks and higher functions to be 
carried out. The parietal association area analyses spatial co-ordinates of the body in relation 
to its surroundings (Guyton 1991) while the temporal association area processes shape and 
form recognition (Clark et al. 2010). Both areas are involved in language comprehension. 
The prefrontal association cortex functions in close association with the motor cortex to plan 
complex sequences of movements and mediates working memory and decision making 
(Fuster and Alexander 1971). The limbic association area, which combines the anterior pole 
of the temporal lobe, the ventral portions of the frontal lobe and the cingulate gyri, is 
involved with processing emotions, and ascribing salience to stimuli so influencing behaviour 
and motivation (Mesulam 1998). The cingulate gyrus consists of an anterior and posterior 
part; the anterior cingulate appears to be involved in the regulation of emotional and 
cognitive behaviour (Allman et al. 2001) and the posterior cingulate is reported to play a role 
in visuospatial and somatosensory attention (Vogt et al. 1992), although functional imaging 
has shown that it is also activated by emotional stimuli (Maddock et al. 2003). 
1.1.3.2. Memory and acetylcholine 
Memories may be categorised as long-term (permanent or more stable storage of memories), 
short term (recall for recent events), or working (information is stored for seconds to minutes 
only). In 1976, John Anderson further categorised long-term memory as explicit 
(declarative), which involves the conscious recollection of previously stored experiences, or 
implicit (procedural) which occurs subconsciously. Explicit memory can be further divided 
into episodic and semantic memory (Tulving 1972). Episodic memory allows the recollection 
of specific personal events or episodes and the context in which they occurred. In contrast, 
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semantic memory relates to what one knows about the world including concepts and facts, 
and knowledge of one self, such as where one lived or was born.       
A number of processes are involved in the successful storing of memories. These include 
sensory uptake of information (Vallar and Papagno 2002), its encoding (Squire 1982), further 
consolidation (Squire 1987) and retrieval (Tulving and Markowitsch 1998). Various neural 
correlates have been proposed for each of these components, with medial temporal lobe 
structures, particularly the hippocampus being central to this process (Moscovitch et al. 
2005). At a molecular level, results from previous studies support the theory that the 
neurotransmitter acetylcholine (ACh) modulates cognitive functions such as memory, with 
deficits in cortical cholinergic transmission being shown to cause learning and memory 
impairment in humans (Drachman and Leavitt 1974). Meanwhile enhancement of central 
cholinergic transmission improved cognitive performance in elderly patients (Drachman 
1977). Studies such as these and the demonstration of reduced pre-synaptic cholinergic 
markers in the cortex of early onset AD patients (Bowen et al. 1976), were in line with the 
later proposed cholinergic hypothesis of AD (Bartus et al. 1982), as described later. However, 
the relationship between ACh and learning and memory is complex, and subsequent studies 
have suggested that there is a ‘biphasic’ modulation of memory processes by hippocampal 
ACh; with cholinergic activation promoting information processing in working memory, and 
a decrease in activity, contributing to consolidation of information (Buzsaki 1989; Marighetto 
et al. 1993). This relationship may be further complicated by the influence of ACh on 
attention (Wenk 1997).  
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1.1.4. Pathology and pathogenesis of AD 
1.1.4.1. Gross external brain changes  
External examination of the AD brain demonstrates cerebral atrophy, with thinning of the 
cortical mantle, narrowing of the gyri and widening of the sulci as illustrated in Figure 1.1. 
At a microscopic level, the neuropathological features of AD are extracellular fibrillar 
plaques (neuritic and non-neuritic), intracellular neurofibrillary tangles, neuronal damage and 
loss.  
1.1.4.2. Amyloid plaques  
Extracellular neuritic (senile) plaques range from 20 to 200 µm diameter and are composed 
primarily of a central core of fibrillar Aβ protein, surrounded by a rim of dystrophic neurites 
and reactive astroctytes and microglia. Aβ is a 40-42 amino acid peptide derived from the 
molecule APP which is a widely expressed membrane glycoprotein, and may play an 
important role in synaptic activity and cell adhesion (Soba et al. 2005). 
 
 
Figure 1-1 Gross appearances AD brain compared to that of a normal control 
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Ordinarily, APP is cleaved by the enzymes α- and γ- secretase respectively. This ‘non-beta 
amyloidogenic’ pathway releases soluble APP (sAPPα), into the extracellular space. There is 
however, a competing, ‘amyloidogenic’ pathway. Here, APP is metabolised by the enzymes 
β-secretase, also known as β-APP-site-cleaving enzyme (BACE), and γ- secretase. This 
results in the extracellular release of monomeric beta-sheeted Aβ42, which forms oligomers 
and fibrils, the building blocks of the fibrillar amyloid in neuritic plaques, and more soluble 
Aβ40 which aggregates in blood vessels to cause amyloid angiopathy, a characteristic feature 
of AD. Apart from neuritic plaques, deposits of Aβ may also exist as diffuse amyloid 
plaques. However, unlike neuritic plaques, diffuse plaques are amorphous; they do not 
contain fibrillar amyloid and they are not associated with dystrophic neuritis (Ikeda et al. 
1989; Yamaguchi et al. 1989). In contrast to neuritic plaques diffuse deposits are not readily 
detected with fluorescent stains such as thioflavin S or thioflavin T. 
1.1.4.3. Neurofibrillary tangles and neuropil threads 
NFTs are intraneuronal structures consisting of paired helical filaments 10 nm in diameter, 
whose major component is 4 repeat hyperphosphorylated tau. Tau is a soluble protein that is 
normally concentrated within axons where it promotes microtubule assembly and 
stabilisation. However, its hyperphosphorylation makes it resistant to proteolysis, hence its 
abnormal deposition in the cell body of affected neurons as NFTs. The resulting disruption of 
microtubules is thought to impair flow within the axon, leading to degeneration and loss of 
connectivity of the affected neuron. Neuropil threads are short thread-like structures 
containing paired helical filaments found within distal dendrites.  
Tau pathology is also seen in a number of other neurodegenerative disorders collectively 
known as tauopathies. These include frontotemporal dementia (FTD), corticobasal 
degeneration (CBD) and progressive supranuclear palsy (PSP). Unlike AD, PSP is 
characterised by 3-repeat hyperphosphorylated tau and straight filaments while FTD 
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inclusions contain a mixture of 3 and 4-repeat tau. Mutations in genes encoding tau cause can 
cause FTD and tau haplotypes that are associated with PSP and PD dementia but, to date, 
have not been associated with AD.  
1.1.4.4. Staging of AD pathology 
Information obtained following autopsy of 2,661 brains led the Braaks (Braak and Braak 
1997) to build upon their previous work (Braak and Braak 1991) where they assigned stages 
to the distribution pattern of both Aβ and NFT pathology. They reported that cortical amyloid 
was distributed unevenly throughout the brain. Most frequently, it was found to be deposited 
firstly in the neocortex (Stage A); particularly in the basal portions of the frontal and occipital 
lobes and the perirhinal and ectorhinal regions of the temporal cortex (but not the 
hippocampal formation). In stage B the amyloid deposits were increased in number, 
spreading to involve adjoining neocortical association regions, now including the 
hippocampus. By stage C, amyloid deposits covered all areas of the cortex, including the 
myelin rich primary motor and sensory areas of the neocortex. Figure 1.2 illustrates the three 
described stages of amyloid distribution. Overall, richly myelinated areas of the brain were 
found to contain a lower density of amyloid compared to those sparsely myelinated areas 
such as the association cortex. The hippocampus and other medial temporal lobe structures 
had fewer amyloid plaques when compared to other neocortical areas (Braak and Braak 
1991).  
As with amyloid deposits, poorly myelinated areas had a higher density of NFTs than those 
rich in myelin. However, the distribution and progression of NFT pathology in the AD brain 
differs to that of amyloid plaques targeting inferior frontal areas at a later stage, as illustrated 
in figure 1.3. NFT formation spreads in a more predictable manner than amyloid plaque 
deposition, with only small variation between individuals. 
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Figure 1-2 Distribution pattern of amyloid deposits 
 
      
Darker shading indicates increased number of amyloid deposits: Braak H, Braak E. 
Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol (Berl) 1991; 82: 
239-59. 
Six stages have been assigned to the spread of NFTs, starting with cells in the transentorhinal 
region of the temporal cortex (stage I). This is followed by NFT deposition in the entorhinal 
region (stage II), and then the hippocampus (CA1 sector) and temporal proneocortex (stage 
III). Only at the next stage (Stage IV), are the adjoining neocortical (association) areas 
affected, with the pathology then spreading superolaterally (stage V) when almost all 
components of the hippocampal formation are involved. Finally the primary areas of the 
neocortex (stage VI) are affected. 
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Figure 1-3 Distribution pattern and stages of neurofibrillary changes  
 
Transentorhinal (I-II)        Limbic (III-IV)                        Isocortical (V-VI) 
 
 
1.1.4.5. Synaptic loss and the Cholinergic hypothesis 
Although Alzheimer first described the pathological aggregates of Aβ and NFTs in 1906, 
further investigation into the neurochemical imbalances involved in AD brains only began 
much later in the 1960s. Over the following years various investigators confirmed a pre-
synaptic deficit in cholinergic transmission, as evidenced by reductions in the enzyme 
responsible for ACh synthesis (choline acetyltransferase (ChAT)) (Bowen et al. 1976; Davies 
and Maloney 1976). This finding along with reported reductions in ACh release (Nilsson et 
al. 1986) and the emerging importance of ACh in learning and memory, led to the cholinergic 
hypothesis of Alzheimer’s disease (Bartus et al. 1982). This hypothesis proposed that 
degeneration of cholinergic neurones in the basal forebrain (nucleus basalis of Meynert) and 
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the resulting loss of cholinergic neurotransmission led to the functional cognitive impairment 
in AD, a viewpoint supported by subsequent studies (Terry et al. 1991).  
1.1.4.6. Amyloid cascade hypothesis 
A central role of Aβ deposition in the pathogenesis of AD was formally introduced as the 
amyloid cascade hypothesis (Hardy and Allsop 1991; Hardy and Higgins 1992). This 
hypothesis proposed that it is primarily the deposition of Aβ (due to abnormal APP 
processing) that leads to the hyperphosphorylation of tau and subsequent neurofibrillary 
tangle formation. Neuronal death and cell loss then follow, ultimately resulting in the clinical 
features of dementia. In apparent support of this hypothesis and sequence of events is the 
observation that mutations of the APP, PSEN1 and PSEN2 genes, which increase amyloidβ42 
formation and the proportion of amyloidβ42: amyloidβ40, are associated with the 
manifestation of AD in families. Additionally, Down’s syndrome (trisomy 21) cases under 
the age of thirty-five (Mann and Esiri 1989) and as young as thirteen have been found to have 
diffuse cortical amyloid plaques, developing neurofibrillary tangles only at a later stage 
(Rumble et al. 1989).  
Despite these observations, a number of concerns have been raised regarding the amyloid 
cascade hypothesis, many questioning the importance of Aβ and its accumulation in both 
driving the disease process and causing symptoms. For example, the density of amyloid 
deposits in the brain does not correlate well with the degree of cognitive impairment in 
individual subjects, (Mufson et al. 1999) and indeed, many cognitively healthy elderly people 
without any signs of AD have abundant senile plaques in their brains (Davis et al. 1999). In 
contrast, studies have shown a good correlation between NFT density and cognition (Nagy et 
al. 1995), suggesting that it is NFTs rather than Aβ that is central to neuronal death in AD 
(Trojanowski 2002). Additionally, the distribution of amyloid plaques does not correspond 
 29 
well with that of tangles in Braak staging.  However, an alternative explanation has been put 
forward to explain the apparent poor correlation between fibrillar amyloid load, tangle 
formation, and levels of cognition, namely that it is soluble oligomers of Aβ rather than 
insoluble fibrils that are responsible for the synaptic dysfunction in the brains of AD patients 
(McLean et al. 1999; Hardy and Selkoe 2002). It has been proposed that these soluble Aβ 
peptides negatively alter the cholinergic system at multiple sites including ACh synthesis, 
release and at the receptor level (Auld et al. 2002). Amyloid plaques may in fact be 
protective, acting to take oligomers out of circulation and so protect neurones.  
1.1.4.7. Microglia, inflammatory mediators and oxidative stress 
Apart from Aβ plaque deposition, NFT formation and loss of cholinergic neurons, other 
factors are important in the neurodegenerative process of AD, such as the functioning of 
microglia and inflammatory mediators. Microglia are the central nervous system’s intrinsic 
macrophages and are found in close association with Aβ plaques. In health, microglia are in a 
resting state. However, following acute neuronal injury microglia are activated and play a 
neuroprotective role. Uncertainty remains, however, regarding the role of microglia in the 
chronic inflammatory response associated with AD. It is debated whether activated microglia 
are primarily protective, phagocytosing and clearing Aβ oligomers and deposits in neuritic 
plaques (Haga et al. 1989) or whether they are mainly a source of damage via cytokine 
release. The amyloid cascade/ neuroiflammation hypothesis (Akiyama et al. 2000) proposes 
that Aβ deposited extracellularly as senile plaques activates microglial cells, which then 
produce potentially neurotoxic substances such as reactive oxygen free radicals and nitric 
oxide, proinflammatory cytokines such as TNFα and IL1b and other inflammatory mediators.  
These neurotoxic species activate kinases leading to tau phosphorylation resulting in NFT 
formation and synaptic loss.  
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1.1.5. Clinical features and diagnosis 
The clinical features of AD include a progressive worsening of short term recall and 
deterioration of one or more other cognitive functions including language, motor skills, 
perception and executive function. AD can also lead to altered patterns of behaviour, 
depression and anxiety. Symptoms of AD can range from mild, where patients have mild 
memory loss and word finding difficulties that interfere very little with their everyday 
activities, to severe where progressive cognitive decline prevents them from carrying out 
activities of daily living such as feeding themselves or getting dressed.  AD may be 
categorised as being mild, moderate or severe depending on scores obtained on mini- mental 
state examination (MMSE) testing.  
In order to make a definite diagnosis of AD, the National Institute of Neurological and 
Communicative Disorders and Stroke - Alzheimer’s Disease and Related Disorder 
Association (NINDS-ADRDA) criteria (McKhann et al. 1984) require evidence of 
progressive cognitive decline in life and histopathological evidence of amyloid plaques and 
NFTs obtained either from biopsy or at autopsy. Practically, obtaining histopathological 
evidence during life is seldom feasible and so patients are assigned a diagnosis of clinically 
probable AD based on symptoms and signs.  A review of 13 published studies with follow up 
and/or pathology as the standard of truth reported the average sensitivity and specificity of 
the clinical diagnosis of AD as 81% and 70% respectively (Knopman et al. 2001). Along with 
the NINCDS-ADRDA criteria, the other widely recognised clinical diagnostic criteria for AD 
are those of the Diagnostic and Statistics Manual of mental disorders, fourth edition (DSM-
IV).  
The primary role of conventional imaging such as computerised tomography (CT) and 
magnetic resonance imaging (MRI) in the clinical setting is to detect atrophy and exclude 
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structural causes of dementia that are potentially reversible and treatable, rather than to 
confirm a clinical diagnosis.   
 
1.1.6. Treatment in AD 
1.1.6.1. Licensed drug therapy  
Established acetylcholinesterase inhibitors including donepezil, rivastigmine and galantamine 
(the latter also acting as an agonist at nicotinic receptors) are used for the symptomatic 
treatment of AD. This pharmacological approach is aimed at increasing ACh levels in the 
brain that are reduced as a result of cholinergic neuronal loss. An alternative therapeutic 
approach is to block glutamatergic transmission, as over stimulation by this neurotransmitter 
is thought to cause neuronal dysfunction and possibly neuronal death in AD (Greenamyre and 
Young 1989). The drug memantine is an NMDA (glutamate receptor) antagonist previously 
licensed for use in patients with moderately severe to severe AD. The acetylcholinesterase 
inhibitors were licensed for use in mild to moderately severe AD. Previously, restrictions of 
the use of both acetylcholinesterase inhibitors and memantine issued by the National Institute 
of Clinical Excellence (NICE), limited the number of people in the National Health Service 
(NHS) treated with these drugs. At that time it was recommended that acetylcholinesterase 
inhibitors were to be used patients with AD of moderate severity only, and memantine in 
those with moderately severe disease who were being treated as part of a well designed 
clinical trial. However, pressure from patient groups, carers and physicians has resulted in 
review and re-appraisal of these guidelines. The most recent guidelines state that donepezil, 
galantamine and rivastigmine are now recommended as options for managing mild as well as 
moderate AD, and that memantine is now recommended for managing both severe AD and 
those with moderate AD who cannot take acetylcholinesterase inhibitors. However, even with 
these changes in NICE guidelines, the search for alternative therapies remains a priority in 
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dementia research with a particular focus on developing new treatments that may alter the 
underlying disease process. Most of these therapeutic strategies are at a research stage only 
and have yet to be used routinely in the clinical setting. They include the use of secretase 
inhibitors targeted at β and γ-secretase, chelation therapy aimed at disrupting fibrillogenesis, 
and Aβ immunotherapy. Unlike cholinesterase inhibitors that are targeted at replacing a 
specific chemical deficit, the aim of these therapies would be to halt or even reverse disease 
progression in patients with AD by targeting key components of the neurodegenerative 
process. 
1.1.6.2. Immunisation 
Schenk et al. were the first researchers to demonstrate the reduction of pre-existing Aβ 
plaques in older PDAPP (transgenic platelet-derived growth factor promoter expressing 
amyloid precursor protein) mice after active immunisation with synthetic human Aβ42  
(Schenk et al. 1999). These mice over express APP and develop senile plaques similar to 
those found in humans with AD. In addition, they found that younger immunized PDAPP 
mice never developed amyloid plaques. Other work in transgenic mice models of AD 
demonstrated that not only was amyloid burden reduced by both active and passive 
immunisation, so was cognitive decline (Janus et al. 2000). However, an improvement in 
cognition in PDAPP mice has been noted after immunisation without a demonstrable 
reduction in amyloid burden – possibly due to oligomer clearance (Dodart et al. 2002). While 
these mice over express APP, they develop little neurodegeneration, even with extensive 
amyloid deposition (Irizarry et al. 1997). Additionally, the transgenic murine models of AD 
that are based on the over expression of abnormal proteins associated with FAD, rarely if 
ever develop NFTs and so are imperfect models of AD (Eriksen and Janus 2007). Finally, 
one must consider whether cognitive deficits detected during the behavioural assessment of 
transgenic mice are truly reflective of those found in human patients. However, although they 
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may not the most reliable of models when comparing to humans, immunisation studies in 
mice provide a starting point, particularly as human immunisation studies have proven more 
difficult to conduct.  
A phase IIa trial in which AD patients were vaccinated with AN1792 (synthetic Aβ peptide) 
was complicated by a minority of patients developing meningoencephalitis (Gilman et al. 
2005). Promisingly, the small number of post mortem studies done on vaccinated patients to 
date have shown a dramatic reduction of both diffuse and neuritic plaques in their neocortical 
areas in keeping with mouse models of active immunisation (Ferrer et al. 2004). The 
meningoencephalitis seen in patients after active immunisation was thought to be secondary 
to a mediated T-lymphocyte response and so now a switch to passive administration of 
monoclonal antibodies to Aβ has been employed. Postulated methods of clearance of Aβ 
from brain include Fc-mediated phagocytosis of Aβ by microglial cells (Bard et al. 2000), a 
‘peripheral sink’ mechanism (DeMattos et al. 2001) and disruption of the fibrillation process 
thereby preventing the aggregation of fibrillar amyloid into plaques (Bacskai et al. 2002).  
 
1.2. Mild cognitive impairment (MCI) 
1.2.1. Clinical features and diagnosis  
Nearly a century after Alois Alzheimer presented the clinical and neuropathological 
characteristics of the eponymous disease, the term ‘mild cognitive impairment’ was formally 
introduced. Although there have been several different operational definitions of this term, 
the general consensus is that it refers to a transitional state between the cognitive changes 
associated with normal ageing and dementia.  
Eighty percent of those patients categorised with amnestic mild cognitive impairment (aMCI) 
by Petersen’s criteria (Petersen et al. 2001) (memory complaint, objective memory 
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impairment for age, normal general cognitive function, intact activities of daily functioning 
and not demented) developed AD over a period of 6 years, and overall aMCIs convert to AD 
at a rate of 10-15% per year compared with healthy controls who convert to AD at a rate of 1-
2% per year (Petersen et al. 1999). Although the most common form of MCI is amnestic or 
aMCI, other cognitive domains (multiple with or without memory impairment or single non-
memory domains) may be affected, but none sufficiently severe to fulfil the diagnosis of 
dementia.  
 
1.2.2. Pathogenesis and prognosis 
Some clinicians argue that MCI is simply the pre-clinical phase of dementia. However, it is 
important to recognise that not all patients diagnosed as having MCI progress to dementia 
and a proportion revert back to normal cognitive functioning. This may be due to the fact that 
by its current definition, MCI is a heterogeneous condition with different subtypes and 
different aetiologies underlying each clinical subtype. For example, the results of 
neuropathological studies performed at autopsy on patients diagnosed with aMCI (single or 
multiple domain), revealed mixed pathology ranging from argyrophilic grain disease (AGD), 
hippocampal sclerosis and vascular change to isolated NFTs and classical AD pathology 
(Petersen et al. 2006). While  aMCI is associated with progression to AD in around 60% of 
cases, non-amnestic MCI more frequently progresses to FTD or other types of dementia 
including vascular and Lewy body dementia (Petersen et al. 2001). 
 
1.2.3. Management of MCI 
Disease progression trials in MCI that have assessed the efficacy of anticholinesterase 
inhibitors, the non-steroidal anti-inflammatory drug (NSAID) rofecoxib and vitamin E have 
been unsuccessful, none demonstrating convincing effects in delaying disease progression or 
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conversion to dementia. These drugs are therefore not routinely used in the management of 
patients with MCI and treatment currently focuses on controlling vascular risk factors, 
treating co-existing depression and medical conditions such as hypothyroidism and 
discontinuing anti-cholinergic drugs, whilst clinically monitoring the patient for symptoms 
and signs of disease progression.  
 
1.3. Neuroimaging in AD and MCI 
1.3.1. Magnetic resonance imaging (MRI) 
MRI allows assessment of structural alterations in the brain such as atrophy, and changes in 
water diffusion to be detected in the AD brain. Neuropathological studies in the earliest 
stages of AD have demonstrated that medial temporal lobe structures, in particular the 
hippocampus, are vulnerable to the formation of NFTs and atrophy. Numerous MRI studies 
have demonstrated significantly lower hippocampal volumes, not only in established AD 
(Chan et al. 2001; de Leon et al. 1995) but also in presymptomatic familial AD cases (Fox et 
al. 1996) and in MCI at higher risk of progressing to AD (Jack et al. 2004). Although 
volumetry of medial temporal lobe structures such as the hippocampus, amygdala and 
entorhinal cortex may be useful in the diagnosis of AD, brain atrophy is not confined to these 
regions. For example, studies have also shown volumes in the cingulate gyrus of AD subjects 
to be lower than that of controls (Baron et al. 2001; Frisoni et al. 2002). Additionally, lobar 
atrophy is not specific of AD or MCI, with both temporal and frontal lobe atrophy occurring 
in other dementias such as FTD.  
Irrespective of its cause, a significant amount of neural cell death is required before atrophy 
becomes visually detectable by structural imaging though voxel based morphometry 
increases the sensitivity of volumetric MRI to aid the early diagnosis of AD. MRI is highly 
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sensitive to changes in regional brain volume and so provides a biomarker to monitor disease 
progression (Fox et al. 2000) while diffusion weighted imaging can sensitively detect 
changes in hippocampal water diffusion in aMCI (Wang and Su 2006).  
 
1.3.2. Emission Tomography 
1.3.2.1. Overview 
Two main functional imaging techniques have been applied to study dementia for the last 20 
years. These are single photon emission computerised tomography (SPECT) and positron 
emission tomography (PET). By detecting the distribution of radionuclides within the brain, 
emission tomography provides a tool that enables us to demonstrate metabolic and 
neurochemical changes that occur in patients with dementia and MCI. For many years, 
SPECT was more readily available than PET though the availability of the latter is now 
rapidly increasing. SPECT is less sensitive than PET and unable to correct for scatter of 
emitted radiation (Messa et al. 1994; Herholz et al. 2002).  
18F-fluorodeoxyglucose (FDG) PET is historically the most widely used PET tracer in the 
study of AD and more recently MCI. In the clinical setting, the Food and Drug 
Administration (FDA) has licensed its use for the discrimination of Alzheimer’s from frontal 
dementias. In a research setting it is also used for the evaluation of patients presenting with 
atypical or unusual symptoms of dementia where diagnostic uncertainty exists. At the time of 
commencing this study, the use of novel radiotracers capable of labelling amyloid protein 
was starting to be explored, particularly with regards to their potential application in 
improving our understanding of the time course of AD pathology and our clinical 
management of patients with both early and established dementia. The most validated and 
widely used radiotracer to date that is capable of binding amyloid protein at the low 
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nanomolar concentrations typically administered for PET studies, is the benzothiazole 11C-
PIB (N-Methyl-[11C]-2-(4′-methylaminophenyl)-6-hydroxy-benzothiazole), also known as 
Pittsburgh Compound B (Klunk et al. 2003). 11C-PIB is a thioflavin derivative that binds to 
extracellular amyloid plaques in post-mortem brain slices but clears rapidly from normal 
brain tissue, making it a valuable in vivo marker of amyloid deposition in life. Increased 11C-
PIB binding has been consistently demonstrated in AD patients (Klunk et al. 2004; Price et 
al. 2005), approximately 50% of people with MCI (Rowe et al. 2007, Kemppainen et al. 
2007), and in patients with dementia with Lewy bodies, although at lower levels of binding 
than that seen in patients with AD (Rowe et al. 2007). However, consistent with reports from 
post-mortem studies (Morris and Price 2001; Crystal et al. 1993), the finding of amyloid 
deposition is not restricted to symptomatic individuals, with up to 25% of elderly healthy 
controls demonstrating 11C-PIB binding in the range of that seen in AD patients (Rowe et al. 
2007; Pike et al. 2007). However, follow-up of such asymptomatic, cognitively intact 
individuals has shown that increased PIB binding is related to progression to very mild 
dementia, independently of age (Morris et al. 2009), suggesting that increased PIB binding is 
not a benign process.  
The aim of this thesis was to test the following hypotheses;  
‘PET imaging provides a reliable in vivo biomarker for the early detection and monitoring 
of disease progression and treatment efficacy in AD and MCI’. 
‘Inflammation can be detected with PET in a significant proportion of MCI cases’.  
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2. Methods 
 
2.1. Principles of PET 
PET is a nuclear medicine technique that allows quantitative images of functional processes 
within the body to be created. It is based on the detection of a radiolabelled biologically 
active compound (exogenous tracer) that emits positrons. Images of tracer concentration are 
ultimately reconstructed by computer analysis allowing the study of specific physiological 
processes in vivo. Developing upon the concept of emission and transmission tomography 
introduced by David Kuhl and Roy Edwards in the late 1950s, tomographic imaging 
techniques were further developed over the next two decades. In the early 1970s, 
investigators at Washington University, directed by Michel TerPogossian and in 
collaboration with Michael Phelps and Edward Hoffman developed the first successful PET 
machine for human studies.  
 
2.1.1. Data acquisition 
2.1.1.1. Isotope decay and annihilation events  
In order to acquire a PET image, a radiolabelled tracer is either inhaled or injected into the 
body. As the radioisotope decays, each decay event results in the emission of a positron. 
After travelling a short distance (1-6 mm) within the body the positron collides with a 
neighbouring electron resulting in the annihilation of both particles. The rest mass of the 
positron and electron is conserved as energy, by the emission of two annihilation photons 
(also termed as gamma (γ) rays, as they fall within the γ-ray region of the electromagnetic 
spectrum), each of 511 keV. The photons are given off at close to 180◦ in opposite directions, 
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and it is therefore possible to localise their source along the straight line of co-incidence, 
known as the line of response (LOR).  
2.1.1.2. Co-incidence detection and timing resolution 
During a PET study, the subject is normally positioned in the tomograph before the 
administration of the tracer. The tomograph consists of a cylinder of detectors arranged in 
rings. Different types of detectors are used to measure the total energy deposited by the 
photons passing through them, converting this energy into a measurable signal. The most 
common of these is the scintillation detector, which consists of an inorganic crystal (e.g. 
bismuth germinate oxide (BGO) as used in this study) mounted on a set of photomultiplier 
tubes. The efficiency of these detectors will in part determine the sensitivity of the scanner.  
A true or real event is the detection of two photons originating from a single annihilation 
event that falls within the set co-incidence timing window. Because the two co-incident 
photons can potentially be emitted from anywhere within the scanner field of view (FOV), 
the distance travelled by each of these photons before detection will be different. This must 
therefore be taken into account when adjusting the co-incidence timing window thereby 
allowing both events to be counted as a co-incidence as opposed to being disregarded as a 
single event (normally 4-18 ns).  
2.1.1.3. Random and scattered emissions, and multiple co-incidences 
Three types of events other than true emissions may be detected and therefore will need to be 
corrected for prior to image analysis. They are;  
1. Random emissions or false co-incident events 
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This refers to the detection of two photons that did not originate from a single annihilation 
event. They are a consequence of having a large co-incidence timing window and add 
uncorrelated background counts to a PET image thereby reducing the image contrast. 
2. Scatter emissions 
These are true co-incidence events from a single annihilation point, but one or both of the 
photons undergo Compton scattering (as they pass through the body) within the imaging 
FOV before entering the detector. They therefore misrepresent the true activity distribution 
within the FOV which leads to worsening of image contrast by attenuation of the signal.  
3. Multiple co-incidences 
Although only two detectors need to be activated within the co-incidence time window to 
register a valid co-incidence, at high count rates it is possible that three or more are involved 
and in such cases options include either randomly selecting one of the possible LORs or 
disregarding the event altogether. The total number of all events (i.e. true, random, scattered) 
detected by the co-incidence circuit in a PET scan are known as prompt co-incidences.  
2.1.1.4. 2D and 3D data acquisition 
Multi ring BGO scanners incorporate annular shields of lead or tungsten (septa) that are 
positioned between detector rings. However, although these septa shield the detectors from 
high levels of scattered and random coincidences, they also eliminate the detection of wide- 
angle line of coincidences and so limit the scanners to 2D acquisition. Multi-ring PET 
scanners with retractable septa allow the acquisition of both 2D and 3D PET data. By 
increasing the co-incidence count rates, 3D PET is more sensitive than 2D PET and is now 
used routinely in all brain scans, including those in this study. The increased sensitivity of 3D 
PET allows a reduction in both the imaging time and the amount of radioactivity injected per 
 41 
study compared to 2D PET. However, it is estimated that 45% of all measured coincidences 
with 3D PET are due to scatter compared to 15% with 2D PET. It is primarily for this reason 
that 2D PET is currently preferred for use in whole body studies, particularly those with 
heavier patients.  
2.1.1.5. Data Collection  
When a valid event is detected by a pair of detectors it is conveyed to sorting hardware that 
writes the raw data as either list mode, where each event is individually written to a file with 
information about the location and the time it occurred, or histogram mode where a memory 
location is assigned to each possible LOR and each time a valid event is detected in that LOR 
its memory location is incremented by one. However, there is a limit to the rate at which 
events may be processed. During the period of time the detector electronics take to process 
each event, some events that occur too close together will be missed. The losses due to this 
‘dead time’ may become quite significant at higher count rates.  
 
2.2. Data Correction 
The co-incidence detection data is binned into sinograms for reconstruction into images. 
However, to produce an image where each voxel value represents the true tissue activity 
concentration, a number of corrections need to be applied to the raw sinogram data prior to 
image reconstruction including normalisation and attenuation and scatter correction.  
 
2.2.1. Normalisation   
Normalisation corrects for the non uniformities in detector sensitivities. Practically, a ‘blank’ 
scan is acquired each day prior to scanning, where positron emitting rods aligned parallel to 
the axis of the tomograph are rotated about the axis of the tomograph so that a uniform source 
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is provided to the detectors. The relative difference in detection rates allows the differences in 
detector sensitivity to be estimated, and this information is then used to correct registered 
counts by simple scaling.  
 
2.2.2. Scatter and attenuation correction 
The inclusion of scatter within reconstructed data lessens contrast between regions and may 
lead to inaccuracies in the measurement of regional activity concentration. However to 
eliminate all scattered events, PET detectors would need extremely good energy resolution 
(i.e. to only accept events with an energy of 511keV). Practically, most BGO scintillation 
detectors used in PET have an energy resolution of 20-25% and accordingly, the fraction of 
scattered events detected can range from 15 to 50%. Therefore scatter correction techniques, 
which estimate the distribution of scattered radiation, are employed to remove them from the 
image; they are the most difficult type of event to correct for. 
The process by which true co-incidences are not detected due to the absorption of 511keV γ-
rays within the body is called attenuation. The most accurate way to determine the 
attenuation correction is through direct measurements. A transmission scan lasting five to ten 
minutes is performed with the patient in the scanner prior to injection of the radiotracer. In 
these studies, rotating 68Ge rods were used as the positron emitting source for the blank and 
transmission scan.  The ratio of the blank scan counts to the transmission scan counts yields 
an attenuation correction factor that can be applied to each LOR even though the source is 
external to the object. This is because the probability of attenuation is the same for any 
source, independent of its location along the line. The 68Ge rods have a long half-life (t½ 275 
days), and so are retracted behind lead shielding when not in use. Every element in the 
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normalised emission sinogram is multiplied by the attenuation correction factor to obtain the 
attenuation corrected emission scan.  
 
2.2.3. Noise 
Noise in PET images refers to the random, unwanted signal that interferes with the 
processing or measurements of the desired signal. One way of maximising the signal to noise 
ratio and therefore the quality of the reconstructed image would be by increasing the signal 
(i.e. radioactive counts) obtained during the scanning period. However, the total injected dose 
of radioactivity administered is limited by safety constraints and the duration of scanning 
time is limited by the half- life of the tracer and patient comfort. It is therefore desirable to 
minimise noise as far as practical. The scanning protocols used in this work have been 
designed to optimise the balance between radiation exposure to the patient, scanning time and 
camera sensitivity. 
 
2.3. Image reconstruction 
The ultimate goal of image reconstruction is to provide an accurate cross-sectional image of 
the distribution of positron emitting tracer within the body. Using filtered back projection 
algorithms, the information (counts) stored as a sinogram can be reconstructed to form a set 
of 2-D images of the original radionuclide distribution at different time points in the organs 
of interest.  
 
2.4. Spatial resolution 
This refers to the minimum distance that two independent point sources can be distinguished 
as separate and is therefore an index of precision. The resolution for PET scanners may be 
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measured in terms of full width at half maximum (FWHM) and with most PET scanners this 
is in the range of 4-8 mms and is dependent on factors such as the sensitivity of detectors, 
false co-incidence events, scattered emissions, patient motion, positron range and non- 
colinearity.  
The positron range (PR) refers to the distance from the site of positron emission to the site of 
annihilation. The total path that a positron may travel through tissue prior to annihilation is 
longer for higher energy photons and so this PR effect varies with each nucleotide and places 
a lower limit to the spatial resolution that can be achieved in PET. The effect of non- 
colinearity arises because the positron and electron are not completely at rest when they 
annihilate. Therefore rather than being emitted at exactly 180°, the annihilation photons will 
be emitted with a distribution of angles around this. In contrast to the PR effect, non-
colinearity does not depend on radionuclide, as the initial energies of positrons prior to 
annhililation with an electron are irrelevant. 
 
2.4.1. Partial volume effect (PVE) 
This arises as a consequence of the limited spatial resolution of PET scanners and occurs 
when a structure being imaged is smaller (usually 2-3 times smaller) than the scanner’s 
FWHM. There are two components of PVE. The first component relates to the spill-over of 
signal between regions and is known as the ‘point-spread effect’. For instance, because of the 
finite spatial resolution of PET, the image of a small source becomes larger but dimmer than 
its true size. This is because part of this signal from the source ‘spills out’ and is seen in 
neighbouring voxels outside of the source. Reciprocally, there may be ‘spilling in’ of activity 
from neighbouring regions which may or may not match the spill-out. Hence PVEs may lead 
to both under- and over- estimations of radioactivity concentrations within a region, which 
may result in blurring of the image.  
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The second component of PVE is the ‘tissue fraction effect’ that is due to the underlying 
heterogeneity of tissues contained within a voxel. Thus the radioactivity concentration 
measured from any one voxel, will actually represent the weighted average of tissue within 
and surrounding this region (e.g. both grey and white matter) and therefore a combination of 
different kinetic responses of these tissues.     
  
2.5. Radiotracers  
2.5.1. General synthesis 
The radiotracers used in PET studies are produced in a cyclotron. A cyclotron is a particle 
accelerator consisting of two semicircular metal electrodes positioned perpendicular to a 
magnetic field, used to accelerate an electrical charge in a small space. Ultimately, proton 
beams (H+ ions) under the influence of a magnetic field are directed towards a target chamber 
containing a stable chemical isotope. Here they undergo a nuclear reaction with this 
bombardment of protons converting the previously stable target material into an unstable 
radioactive isotope that decays by positron emission. The radioisotopes produced within the 
cyclotron are then transferred to the bio-synthesizer unit and attached to clinically useful 
biological markers.  Prior to its administration, the radionuclide is assessed for quality which 
includes factors such as chemical purity. The most commonly used short-lived positron-
emitting radionuclides include fluorine-18, carbon-11, nitrogen-13 and oxygen-15. These 
have half- lives of 110, 20, 10 and 2 minutes respectively.  
 
2.5.2. Specific radiotracers used in this study 
Several criteria should be met before an agent is further developed for the purposes of in vivo 
brain imaging. These include limited peripheral metabolism, the ability to cross the blood-
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brain barrier and selectivity to one or few pathways. The following radiotracers used for the 
PET studies described in this thesis meet these criteria and each will be discussed in further 
detail in later chapters. 
2.5.2.1. [11C]-PIB  
The benzothiazole 11C-PIB (N-Methyl-[11C]-2-(4′-methylaminophenyl)-6-hydroxy-
benzothiazole), also known as Pittsburgh Compound B, is a thioflavin derivative that has 
been shown to bind to extracellular amyloid plaques in post-mortem brain slices, but not to 
intracellular NFTs at the low nanomolar concentrations typically administered for PET 
studies (Klunk et al. 2003). In vivo studies that have followed have also demonstrated 
increased PIB binding not only in AD patients (Klunk et al. 2004), in whom binding in the 
cortical association areas is increased more than two-fold (Edison et al. 2007), but also in 
50% of people with MCI (Rowe et al. 2007). Other amyloid labelling radiotracers that have 
been developed such as the stilbene derivative 11C-SB-13 (Verhoeff et al. 2004) have been 
shown to bind to amyloid plaques with similar retention patterns to that of 11C-PIB in patients 
with AD. However, the non-specific signal of this radiotracer is higher than that of 11C-PIB 
(Kung et al. 2004). The radiotracer 18F-FDDNP was later shown in vivo to bind not only to 
Aβ but also to NFTs in patients with AD and MCI (Small et al. 2006). However, the specific 
binding signal detected from cortical association areas using this radiotracer is low compared 
with that of both 11C-PIB and 11C-SB-13 potentially limiting its future clinical application. 
Currently 11C-PIB is the radiotracer that is most commonly and successfully utilised in 
studies of subjects with asymptomatic ageing, subjective and mild cognitive impairment, AD 
and other dementias.   
 
 47 
2.5.2.2. [18F]-FDG  
This is the most commonly administered PET tracer in clinical practice, being used not only 
for brain imaging, but also in oncology, where malignant cells show increased glucose 
metabolism compared to normal cells, making it an extremely valuable clinical tool.  In the 
brain, 18F-FDG PET is used to measure regional cerebral metabolic rate for glucose 
(rCMRGlc) where it reflects synaptic activity (Phelps et al. 1979). Numerous FDG PET 
studies that have been performed in AD patients consistently demonstrate temporo-parietal 
and posterior cingulate hypometabolism in over 90% of cases (Minoshima et al. 1995; Heiss 
et al. 1991) and the degree of hypometabolism in AD as demonstrated by FDG PET appears 
to correlate well with neuropsychometry measures (Slansky et al. 1995). Fewer studies to 
date have been performed in patients with MCI, but around 50% of these subjects also show 
temporal and cingulate hypometabolism (Nestor et al. 2003).  
The finding of regional cerebral glucose hypometabolism is not specific to AD. Patients with 
dementia with Lewy bodies (DLB) can show an Alzheimer pattern of reduced rCMRGlc 
(Minoshima et al. 2001) while in FTD, the inferior frontal and temporal lobes and basal 
ganglia are targeted (Jeong et al. 2005).   
 2.5.2.3. [11C]-(R)-PK11195 
11C(R)PK11195 [1-(2-chlorophenyl)-N-methyl-N-(1-methylpropyl)-3-isoquinoline 
carboxamide] is a ligand for translocator protein (TSPO) previously known as the peripheral 
benzodiazepine binding site (PBBS) expressed by activated but not resting microglia (Banati 
2002). The PBBS is expressed only in small numbers in normal brain parenchyma and so it 
provides an in vivo marker of inflammatory response. Areas where activated microglia are 
located include those surrounding injury and distant projection areas of the lesioned pathway 
as well as areas of the brain where microglia are naturally more active including regions 
lacking the blood brain barrier. Few studies have utilised 11C-PK11195 PET in patients with 
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AD, with one reporting the level of binding to be increased in the temporoparietal region and 
posterior cingulate in AD patients compared to controls (Cagnin et al. 2001). 
  
Using the PET tracers 11C-PIB, 18F-FDG and 11C-PK11195, the following studies aim to test 
the hypotheses that PET can be used to detect inflammation in a significant proportion of 
MCI cases, and that it provides a reliable in vivo biomarker for the early detection and 
monitoring of disease progression and treatment efficacy in AD and MCI. 
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3. Microglial activation and amyloid deposition in mild cognitive 
impairment 
 
3.1. Introduction 
Population based studies have consistently shown that patients with episodic memory 
impairment beyond that allowed for normal ageing, but who are not demented (amnestic 
MCI), will convert to AD at higher rates than the general population. With the potential 
development of new treatments targeted at halting or reversing disease progression in AD 
patients, there is now increasing emphasis on identifying those at risk MCI patients, so that 
they may benefit from these treatments (if proven to be effective)  at the earliest possible 
stage. Although the formation of Aβ and NFTs are key features in AD pathogenesis, 
activated microglia are also thought to be important and have been shown to cluster around 
sites of Aβ in human post-mortem brain studies and in transgenic mouse models of AD 
(Haga et al. 1989; Meyer-Luehmann et al. 2008). The precise role of microglial activation 
and its relationship to Aβ remains controversial. Microglia phagocytose dead cells, remodel 
synapses, and remove Aβ fibrils (Paresce et al. 1997) but also have damaging effects, 
releasing cytokines and nitric oxide (McGeer and McGeer 2001). Less still is known about 
their relevance to MCI. 
It is important to remember that the underlying cause of the memory impairment in aMCI 
individuals is varied and although it frequently has a pathological basis, it is not always 
associated with NFTs and Aβ. Pathological studies in aMCI patients have shown changes 
ranging from those diagnostic of AD, DLB and normal pressure hydrocephalus (NPH), to 
cerebral infarction and AGD (Petersen et al. 2006). Therefore, although the majority of 
patients with aMCI who develop dementia progress clinically and pathologically to AD 
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(Jicha et al. 2006; Schneider et al. 2009), it is still important to identify those aMCI patients 
at risk of progressing to other dementias, as they too might benefit from early intervention 
with potential disease modifying agents.  
Increased binding of [11C]-(R)-PK11195 (a PET ligand that is specific for the TSPO), has 
been reported in AD (Edison et al. 2008a) and also in other neurodegenerative disorders such 
as FTD (Cagnin et al. 2004) and PD (Gerhard et al. 2006), indicating that microglia activation 
is a non-selective response to neuronal damage. It is conceivable, therefore, that aMCI 
patients with any significant underlying pathology may show evidence of microglial 
activation. Using the PET radiotracers [11C]-(R)-PK11195 and 11C-PIB the objective of this 
study was to test the hypotheses that: (a) PET can be used to detect inflammation in a 
significant proportion of MCI cases, and (b) the patterns of amyloid deposition and microglial 
activation are related when present in aMCI subjects.  
 
3.2. Methods 
3.2.1. Subjects 
3.2.1.1. MCI subjects   
Fourteen MCI subjects (mean age 66.6 years; SD 9.6) fulfilling Petersen’s criteria for 
amnestic MCI (Petersen et al. 2001) were included in the study (Table 3.1). Subjects were 
recruited from specialist cognitive disorders clinics at the following UK hospitals; 
Hammersmith Hospitals NHS Trust, the National Hospital for Neurology and Neurosurgery, 
St. Margaret’s Hospital and Victoria Hospital. The patients had been referred to these clinics 
for further assessment by either their primary health care provider or hospital physician. Prior 
to their enrolment into the study, and as part of their standard clinical assessment, each 
subject had been assessed by either a senior neurologist or psychiatrist on at least one 
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occasion and had also undergone formal neuropsychometry testing by a neuropsychologist.  
The details of those patients meeting the inclusion criteria and expressing an interest in 
participating in a research study were passed on to the investigators, myself included. The 
inclusion criteria for the study were [1] diagnosis of MCI, [2] age 35-79 and [3] adequate 
visual and auditory acuity to complete neuropsychological testing. The exclusion criteria 
were [1] significant white matter disease (vascular or other) on MRI, [2] current or recent 
history of drug or alcohol dependence or abuse, [3] any medical condition that could 
influence neuropsychological testing, [4] clinically significant major psychiatric disorder 
such as a major depressive disorder, [5] previous or current history of schizophrenia, 
schizoaffective disorder, bipolar disorder or electroconvulsive therapy (ECT), [6] history of 
cancer within the last five years (apart from skin or prostate cancer), [7] contra- indications to 
PET such as pregnancy, [8] contraindications to MRI such as pacemakers. Ethical approval 
for the study was granted by the Hammersmith and Queen Charlotte’s Hospitals ethics 
committee. All patients gave informed written consent prior to their participation and any 
patient incapable of giving informed consent for whatever reason was also excluded from the 
study.  
3.2.1.2. AD subjects 
Twenty-two subjects (mean age 64.9 years; SD 6.4) meeting the NINCDS- ADRDA criteria 
for the diagnosis of probable AD were used for comparison with our MCI group. All AD 
subjects had 11C-PIB PET and of these 15 (mean age 63.7 years; SD 6.0) additionally had 
11C-(R)-PK11195 PK PET. The inclusion criteria for the AD subjects were [1] age 55-79, [2] 
diagnosis of AD based on NINCDS-ADRDA and DSM-IV criteria, [3] adequate visual and 
auditory acuity to complete neuropsychological testing, [4] a reliable care giver who could 
provide information about the patient’s clinical symptoms, [5] completion of standard 
Alzheimer’s disease research centre (ADRC) evaluation. The exclusion criteria were the 
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same as that for the MCI group stated earlier, and again, all patients were required to provide 
written informed consent prior to their inclusion in the study. 
3.2.1.3. Healthy controls 
Fourteen controls (mean age 63.9 years; SD 5.3) were recruited and received 11C-PIB PET as 
part of this project. These subjects were clinically assessed and scanned at the Cyclotron 
Building Hammersmith Hospital. Additionally, 11C-PK11195 PET data from ten controls 
(mean age 60.2 years; SD 9.3) enrolled in separate PET studies at Hammersmith Hospital 
(but still meeting the same inclusion and exclusion criteria for this study) were also used for 
comparison with the MCI group. Because these studies involve the use of ionising radiation, 
it was felt appropriate to use pre-existing data obtained by the same established protocols and 
using the same scanners as the current study for our control group, rather than recruit and 
scan a new control population.  
 
Table 3.1 Demographic details of MCI patients  
 MCI: total MCI: 
AD-range 
PIB 
MCI: 
normal-
range PIB 
AD 11C-PIB 
controls 
11C-(R)-
PK11195 
controls 
Total number 14 7 7 22 14 10 
Mean age 
(years±SD) 
66.6±9.6 69.1±6.4 64±11.9 64.9±6.4 63.9±5.3 60.2±9.3 
Gender:  
Women/total 
5/14 3/7 2/7 10/22 6/14 4/10 
Mean 
duration 
symptoms 
(years±SD) 
4.1±2.1 3.4±0.8 4.7±2.9 5.5±3.8 - - 
Mean MMSE 
(±SD) 
27.7±1.5 28.1±1.4 27±2.2 21.5±3.6 29.8±0.43 29.9±0.32 
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3.2.2. Neuropsychometry tests 
All MCI patients had a comprehensive clinical assessment including neurological 
examination and neuropsychological tests. The clinical criteria for MCI were operationalized 
as (1) subjective memory complaint by the patient, preferably corroborated by an informant, 
(2) objective memory impairment as assessed by performance below age-matched normals on 
at least one neuropsychological measure of memory, (3) preserved general cognitive 
function, (4) intact activities of daily living, (5) not demented according to DSM-IV criteria. 
A strict cut-off score was not applied for the definition of objective memory impairment. 
However, the majority of subjects performed greater than 1.5 standard deviations below the 
appropriate age-matched normative values on tests of memory including the Alzheimer’s 
Disease Assessment Scale (ADAS) Word List Learning test & 30 minute delayed recall 
(Rosen et al. 1984), Warrington short recognition memory tests (WRTM) for words and 
faces, and the immediate & delayed recall of a Rey modified complex figure (Becker et al. 
1987). Other tests included in the neuropsychometry battery (allowing for the assessment of 
other cognitive domains) included the MMSE (Folstein et al. 1975), Digit Span forwards 
(Wechsler 1981), Clock Drawing test (Freedman and Kaplan 1994), Trail Making Part A and 
B (Reitan 1958), 30-item Boston Naming Test (Saxton et al. 2000), letter fluency (FAS) and 
category fluency (animals, birds and dogs) (Benton 1968) and the digit symbol test (Smith 
1982). These tests took approximately 90 minutes to administer and were completed during 
one sitting (with a break of at least ten minutes during session). 
 
3.2.3. MRI scanning 
Each patient and control underwent volumetric T1 and T2 weighted MRIs which were 
obtained with either a 1.5 Tesla GE MRI scanner (pulse sequence: RF-Fast; acquisition 
times TR= 30ms, TE=3ms; flip angle 30 degrees), or a 3 Tesla Philips Achieva MRI scanner 
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(pulse sequence: MP-RAGE; acquisition times TR= 9.6 ms, TE= 4.6 ms; flip angle 8 
degrees). T1-weighted MRI allows structure-function co-registration with 11C-PIB PET 
images while T2-weighted MRI was performed to exclude structural lesions or significant 
white matter disease. MRI scan data from Hammersmith Hospital was collected personally 
and by P. Edison, a clinical research fellow also involved in this study. MRI data from the 
National Hospital for Neurology and Neurosurgery was collected by H. Archer, clinical 
research fellow.   
 
3.2.4. PET scanning 
Permission to administer 11C-PIB and 11C-(R)-PK11195 was obtained from the 
Administration of Radioactive Substances Advisory Committee of the United Kingdom 
(ARSAC). The radiochemical synthesis of both 11C-PIB and 11C-(R)-PK11195 were 
performed by Hammersmith Imanet, Cyclotron Building, Hammersmith Hospital, UK. All 
subjects underwent both 11C-PIB and 11C-(R)-PK11195 PET on separate occasions (mean 
interval between scans 6.4 ± 5.4 weeks). 11C-PIB and 11C-PK11195 PET scan data of AD and 
MCI subjects were collected personally and by P. Edison. Both the analysis of data and 
statistical analysis for this study were performed personally. 
3.2.4.1. 11C-PIB 
All MCI, AD and control subjects were scanned using a Siemens ECAT EXACT HR+ 
tomograph (Siemens 962, Knoxville, TN) in three dimensional acquisition mode which has a 
total axial field-of-view of 15.5 cm. The camera has a transaxial spatial resolution of 5.6 mm 
and an axial resolution of 5.4 mm after image reconstruction. After the subject was placed in 
the scanner and head positioned and immobilised gently with orthopaedic straps so as to 
minimise head motion, a 10-minute transmission scan was performed prior to the injection of 
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the tracer to measure tissue attenuation of 511 keV γ-radiation. A mean dose of 366± 26.8 
MBq 11C-PIB was injected intravenously over 30 seconds which was immediately followed 
by the collection of dynamic data over 90 minutes as 32 time frames (Table 3.2), and 
displayed as sixty-three transaxial planes of 2.46 mm. All data processing and image 
reconstruction was performed using Siemens software. 
Data analysis:  
 1. 11C-PIB target region: cerebellar cortex ratio images: Although diffuse amyloid 
deposits may be found in the cerebellar cortex of AD patients, (Joachim et al. 1989), fibrillar 
deposits are rarely observed in the cerebellar grey matter in sporadic AD cases. Hence, 
cerebellar grey matter does not bind dyes such as Congo red and N-Methyl-[11C]-2-(4′-
methylaminophenyl)-6-hydroxybenzothiazole (PIB) which target beta-sheeted aggregates, 
and only low levels of PIB binding are observed in cerebellar homogenates of AD patients 
and controls (Klunk 2003). We, therefore, used the cerebellar cortex as a reference region and 
parametric images of PIB retention (target region: cerebellar cortex ratio (Ratio)) were 
created by dividing the integral 60-90 minute tracer uptake image, by the integral 60-90 
minute uptake value in the cerebellar grey matter by the following steps, as illustrated in 
Figure 3.1;  
i] Creation of summation images: Firstly (1), summation images were created from the 
dynamic PET data. Two summation images were created; the first (early add image) 
integrated the radioactivity collected over 10-90 minutes, and the second (late add image) 
was a summation of radioactivity over the last 60-90 minutes of the scanning period. These 
images were created using a programme written in Matlab 6. Next, using Statistical 
Parametric Mapping software (SPM2; Wellcome department of Imaging Neuroscience, 
University College London, UK), each MRI was re-orientated along the anterior commissure- 
posterior commissure (AC-PC) line and then (2) segmented into grey matter, white matter 
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and CSF images. The resulting probabilistic grey matter image was binarised in SPM (3) by 
thresholding at 50% probability (i.e. selecting only those voxels that exceed this threshold) 
using the image calculator function. This binarised grey matter image is then used at a later 
stage in the creation of an object map.  
ii] Co-registration and normalisation of PET and MRI images: Both summation PET images 
were co-registered to individual subjects’ T1 weighted MRIs (4). The purpose of this inter-
modality registration is to ensure that both the PET and MRI of each individual are as closely 
aligned as possible, (using mutual information) allowing one to obtain functional information 
from the PET images localised over the anatomical (MRI) images. Using the default settings, 
each individual’s MRI is then transformed to match a standardised space in a process called 
spatial normalisation (5). Using this MRI template, the co-registered PET images and 
binarised MRI probability grey matter image are also normalized into Montreal Neurological 
Institute (MNI) space by applying the same warping parameters. 
 
Table 3.2 11C-PIB dynamic emission scan time frames 
Number of 
frames 
Duration of 
frames (seconds) 
Type Accumulated number 
Frames Time (min:sec) 
1 30  Background 1 0:30 
1 15  Frames 2 0:45 
1 5 Frames 3 0:50 
1 10 Frames 4 1.00 
2 30 Frames 6 2:00 
9 60 Frames 15 11:00 
3 180 Frames 18 20:00 
14 300 Frames 32 90:00 
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Figure 3-1 Flowchart illustrating steps involved in 11C-PIB scan analysis 
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iii] Creation of an object map: 
Using Analyze software, (Mayo Clinic, MN), the binarised grey matter image was convolved 
with an in-house label-based maximum probability brain atlas (Hammers et al. 2003) (6). 
This creates an individualized anatomical atlas for each subject in standard stereotaxic space 
which is used as a template to sample a priori designated regions of interest (ROIs). Figure 
3.2 illustrates the object map. At this stage, the anatomical atlas is superimposed on the late 
add image (in MNI space), and the summated 11C-PIB activity over 60- 90 minutes in the 
cerebellar cortex (reference region) is sampled (7). Finally, the late (60-90 minute) 
summation images were divided by this cerebellar uptake value using the image calculator 
function in Analyze (8), creating a late (target region: cerebellar cortex) ratio image. The 
anatomical atlas is again applied to the ratio image allowing relative PIB retention ratios in 
designated regions of interest to be calculated.  
Rationale of reference selection  
The reference region approach is advantageous because it does not require arterial plasma 
sampling. We used a time window of 60-90 minutes as this has been found to give the most 
robust results with the lowest test- retest variability across cortical regions. Overall, the 
reference region approach provides a robust measure of total: non-specific PIB relative 
volumes of distribution in target brain regions.  
2. ROI analysis: A probabilistic brain atlas was used to delineate our regions of 
interest. This anatomical template is predefined, with brain being divided into 67 regions of 
interest (cortical and subcortical), with cortical structures being subdivided by anatomical 
landmarks. For instance the temporal lobe is divided into 18 separate regions including 
structures of the medial, anterior, lateral and posterior temporal lobe. Similarly, the frontal 
lobe is divided into 12 structures and the parietal and occipital lobes each into six. Sampling a 
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select number of regions only, reduces the potential error introduced by comparisons of 
multiple regions. Therefore, for the purposes of this study, PIB retention was quantified in 
each of the anterior cingulate, posterior cingulate, frontal, temporal and parietal cortices as a 
whole. Additionally, whole brain retention was quantified as an average across all five of 
these regions, although this was not considered as a separate region when performing 
statistical analyses. An automated segmentation technique was chosen as compared to manual 
non- automated methods, as they are less subject to intra-observer variation and do not place 
a practical limit on the size of the study cohorts. Formal partial volume correction was not 
applied to the data. However, by convolving each individual’s MRI with our maximum 
probability atlas, information regarding inter-subject variability is retained, therefore 
reducing the effect of anatomical variations in individual subjects such as atrophy. Figure 3.2 
illustrates the anatomical atlas superimposed on a patient’s MRI scan. 
3.2.4.2. 11C-PK11195 
All subjects were scanned using an ECAT EXACT HR ++ (CTI/Siemens 966, Knoxville, 
TN) PET tomograph (3D mode) with a total axial field of view of 23.4 cm, 95 transaxial 
planes, a transaxial spatial resolution of 4.8 mm and axial resolution of 5.6 mm after image 
reconstruction (Spinks et al. 2000). Subjects received 299±16 MBq 11C-(R)-PK11195, 
injected intravenously over 30 seconds, and scanning was performed in list mode with the 
dynamic images being rebinned over 60-minutes as 18 time frames (30 s background, 1 x 15 
s, 1 x 5 s, 1 x 10 s, 1 x 30 s, 4 x 60 s, 7 x 300s, 2 x 600 s). Prior to injection of the tracer, a 5-
minute transmission scan was performed to correct for tissue attenuation of 511 keV γ- 
radiation.  
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Figure 3-2 Individualized object map superimposed on MRI scan in MNI space. 
               
 
 
Data analysis:  
The following data and statistical analysis was performed personally.   
1. Creation of parametric BP images by supervised clustering technique: Parametric 
images of PK binding potential (BP) were generated by a simplified reference tissue model 
(SRTM), using receptor parametric mapping (RPM) software written in Matlab (Gunn et al. 
1997). Unlike fibrillar amyloid plaques, activated microglia are distributed throughout all 
brain regions in AD, including the cerebellum (Larner 1997), potentially making the selection 
of a suitable reference region for non-specific signal difficult. Recently, a supervised 
clustering technique has been described and was used in this study. This technique derives a 
non-specific uptake tissue reference input function for each subject studied and produces BP 
estimates that are reproducible and comparable to those derived from plasma input (Anderson 
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et al. 2007; Turkheimer et al. 2007). The method uses six predefined kinetic classes to extract 
as a reference region a cluster of grey matter voxels in each individual that exhibits the 
kinetic behavior closest to that of grey matter in a population of healthy controls. These 
classes are non specific grey and white matter, pathological PBR binding, (i.e. tissue with 
intense microglia activation), blood pool, muscle and skull. The supervised clustering 
algorithm avoids regions with specific binding such as association cortex in AD and large 
vessels, and the resulting cluster of voxels is clear of unwanted spurious signals arising from 
areas of the brain known to have a rich density of TSPO receptors such as the meninges.  
i] Creation of summation images: PK summation images, integrating the radioactivity 
collected over 60-minutes were created using a programme written in Matlab 6. This 60-
minute summation image contains blood flow dependent signal, providing good anatomical 
detail, so enabling accurate co-registration. As with PIB analysis, the next step in image 
processing involves segmenting the MRI in SPM (using same re-orientation parameters as 
with PIB analysis) into grey, white matter and CSF images and binarising the probabilistic 
grey matter image.  
ii] Co-registration and normalisation of PET and MRI images: The parametric PK BP images 
and 60-minute summation images were co-registered to each subject’s MRI and spatial 
normalisation and creation of a grey matter object maps were performed by the same methods 
described for analysis of PIB images.  
2. ROI analysis: Lastly, BPs were quantified in the same regions described earlier, 
being the anterior cingulate, posterior cingulate, frontal, temporal and parietal cortices and 
whole brain.  
 
Statistical Analysis: 
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Statistical tests were performed using SPSS for Windows 14.0 statistical software. Repeated 
measures analysis of variance (ANOVA) was applied to test for global differences in PIB and 
PK binding between MCI groups and controls, using the Greenhouse Geisser factor to correct 
for variance heterogeneity across regions.  Univariate analysis of variance was used to detect 
significant differences in regional PIB and PK binding between groups, using age as a 
covariate and the P plot method (Turkheimer et al. 2001) to control for multiple comparisons.  
Because of the heterogeneity of PK binding within the two MCI subgroups, (those with 
increased ‘AD-range’ and normal ‘control-range’ PIB binding), PK BPs in MCI subjects are 
also described on an individual basis. Regional PK binding was considered raised if ≥ 2 SD 
greater than the control mean BP for that region.  
Pearson’s rank correlation coefficient was used to interrogate the correlation between PIB 
and PK binding in MCI subjects. Spearman’s rank correlation coefficient was used to assess 
the correlation between these PET measures and MMSE scores and duration of symptoms.  
 
3.3. Results 
3.3.1. 11C-PIB retention 
Visual inspection of the 60-90- minute PIB ratio images, showed increased uptake in seven of 
14 (50%) MCI subjects and this was confirmed with quantitative analysis; these subjects 
demonstrated nearly two-fold increases in PIB uptake ratio values compared to controls in 
areas including the anterior and posterior cingulate, frontal and parietal cortices. The seven 
MCI patients with increased uptake were, therefore, considered as a subgroup, having mean 
PIB binding in an ‘AD-range’ and significantly greater than control mean binding in all 
cortical ROIs (p<0.001). The remaining seven MCI subjects had normal cortical PIB uptake 
visually and quantitatively when compared to controls (p= 0.69) (Table 3.3). Of note, two of 
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the 22 AD subjects had regional 11C-PIB uptake within the control-range and one control (64 
year-old man) had increased PIB retention (> 2SD greater than control mean) in the anterior 
cingulate, frontal and temporal cortex. Individual PIB uptake values in all 14 MCI patients 
are detailed in Appendix 1. 
 
 
Table 3.3 Mean 11C-PIB retention values in AD, MCI and healthy controls   
 AD 
(n=22) 
MCI 
(n=14) 
MCI: AD-
range (n=7) 
MCI: 
normal-
range (n=7) 
HC 
(n=14) 
Ant cingulate 2.23±0.42 1.64±0.56 2.14±0.33† 1.15±0.06 1.17±0.12 
Post cingulate 2.22±0.40 1.67±0.59 2.19±0.34† 1.16±0.09 1.20±0.07 
Frontal 2.06±0.37 1.54±0.49 1.95±0.34† 1.12±0.02 1.10±0.07 
Temporal 1.86±0.34 1.45±0.43 1.78±0.39† 1.11±0.04 1.12±0.03 
Parietal 2.02±0.37 1.51±0.50 1.92±0.41† 1.11±0.04 1.11±0.05 
Whole brain 1.96±0.34 1.49±0.46 1.86±0.37† 1.13±0.03 1.12±0.05 
 
Values = mean ± SD; † p< 0.001 for MCI:‘AD-range’ vs. controls 
 
 
 
3.3.2. 11C-(R)-PK11195 binding 
Co-registration of the PK BP image with MRI in one MCI subject who had normal PIB 
uptake (55 year-old man) was unsatisfactory. He was, therefore, excluded from further PK 
PET analysis. Repeated measures ANOVA showed a significant difference (p=0.036) 
between mean PK BPs in ‘AD-PIB range’ MCI patients and controls. ‘AD-PIB range’ MCI 
patients had significantly increased mean PK binding in the anterior cingulate, posterior 
cingulate and frontal cortex. However, only frontal cortex PK uptake remained significantly 
raised after a correction for multiple comparisons was applied. There was no difference 
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between mean regional PK binding in the ‘AD-PIB range’ MCI and AD groups (p=0.31), or 
between ‘normal-PIB range’ MCI and controls (p=0.67). Grouped mean PK BPs in the 
subject groups are shown in Table 3.4. Individually, PK binding was significantly increased 
in five of 13 (38%) MCI subjects, three with ‘AD- range’ and two with ‘normal-range’ PIB 
binding (Appendix 2).  
PK BP values in the MCI subgroups compared to that of controls in the frontal cortex are 
displayed in figure 3.3. PET images showing PK binding in MCI patients are displayed in 
figure 3.4.  
 
 
Table 3.4 ROI 11C-(R)-PK11195 BP values in AD, MCI subjects and controls  
 AD 
(n=15) 
MCI 
(n=13) 
MCI: AD-
range 
(n=7) 
MCI: 
norm-
range 
(n= 6) 
Controls 
(n=10) 
p 
value 
A cingulate 0.46±0.16 0.48±0.16 0.53±0.19 0.43±0.12 0.41±0.09 0.03 
P cingulate 0.51±0.18 0.54±0.15 0.59±0.16 0.47±0.12 0.45±0.10 0.03 
Frontal 0.43±0.11 0.44±0.15 0.48±0.16 0.39±0.14 0.35±0.07 0.02‡ 
Temporal 0.43±0.08 0.43±0.14 0.46±0.13 0.39±0.14 0.37±0.07 0.14 
Parietal 0.38±0.11 0.41±0.14 0.43±0.14 0.39±0.16 0.35±0.08 0.10 
Whole brain 0.43±0.10 0.44±0.14 0.47±0.14 0.40±0.14 0.37±0.07 0.06 
 
Values = mean ± SD: p value is for MCI: ‘AD-range’ vs. controls 
‡ p value significant after correction for multiple comparisons 
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3.3.3. Correlations  
There was no correlation between individual regional PK binding and PIB retention in our 
MCI groups. Additionally, no correlation was found between duration of symptoms or 
MMSE scores with either PIB retention or PK binding in our ‘AD-PIB range’ subgroup.                                    
However, a significant correlation was detected in the PIB-negative subgroup, where lower 
MMSE scores correlated with higher 11C-(R)-PK11195 binding in the anterior cingulate 
(Spearman’s rho, ρ= -.812, p< 0.05) and temporal cortex (Spearman’s rho, ρ= -.812, p<0.05) 
(Figure 3.5 and Appendix 3).  
 
Figure 3-3 Scatter plot showing 11C-(R)-PK11195 binding potentials in frontal cortex of 
controls, and MCI subgroups; PIB-positive (+ve) and PIB-negative (-ve) MCI. The dotted 
horizontal line shows controls’ mean + 2SD. 
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3.3.4. Follow-up 
During a 24-36 month follow-up period after their baseline PIB PET scan, three out of five 
(60%) PIB-positive MCI subjects clinically converted to AD. None of the three PIB-negative 
MCI subjects who were also followed-up for two to three years converted to AD, although 
they continued to fulfill the criteria for a diagnosis of MCI during this time. These three 
include the two MCI subjects with regionally increased PK binding but normal PIB uptake.  
 
 
Figure 3-4 11C-(R)-PK11195 BP and corresponding PIB ratio images in two PIB-positive 
mild cognitive impairment (MCI) patients; MCI-I has normal PK binding and MCI-II has 
increased PK binding. 
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Figure 3-5 Correlation between 11C-(R)-PK11195 binding and MMSE in the anterior 
cingulate cortex in A) PIB positive MCI and B) PIB negative MCI, and in the temporal 
cortex in C) PIB positive and D) PIB negative MCI. 
                       
           
 
 
3.4. Discussion  
In this combined 11C-PIB and 11C-(R)-PK11195 PET study, seven (50%) of our 14 amnestic 
MCI subjects had evidence of increased amyloid deposition. This is consistent with 
neuropathological studies which report Aβ deposition in a significant proportion of MCI 
subjects (Markesbery et al. 2006; Petersen et al. 2006) and with the concept that amyloid 
deposition occurs early in the clinical evolution to AD. During a two to three year follow-up, 
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three out of five of our PIB-positive but no PIB negative MCI patients converted to clinically 
probable AD.  
Previous PIB PET studies have reported increased PIB retention in 10 to 25% of cognitively 
normal subjects (Mintun et al. 2006; Rowe et al. 2007). The finding of increased PIB uptake 
in asymptomatic subjects is consistent with post mortem studies, where AD type pathology 
has been reported to be present in an age dependent manner in up to 30% of cognitively older 
adults (Price and Morris 1999; Bennett et al. 2006). An 11C-PIB PET study performed in 31 
AD, 33 MCI and 32 healthy ageing (HA) participants (Pike et al. 2007), found that 22% of 
the HA participants (mean age 71.1 years) showed increased cortical PIB binding. Although 
asymptomatic, when compared to the PIB negative HA subjects, those with PIB-positive 
scans performed 0.8 SD worse on the composite episodic memory scores (p= 0.023). In a 
much larger study (Morris et al. 2009), where 159 asymptomatic, cognitively intact 
individuals with a mean age of 71.5 years were followed up, it was shown that increased PIB 
binding is related to progression to very mild dementia (CDR 0.5 status) independently of 
age. Together, these findings suggest that increased PIB binding as a marker of amyloid 
deposition is not a benign process even in the currently asymptomatic, although it may be 
several years until symptoms emerge. In our study, only one of 14 healthy controls showed 
increased PIB retention; this targeted the anterior cingulate, frontal and temporal cortices. 
Our relatively young control group (mean age 63.9;SD 5.3) might account for the lower 
prevalence of significant PIB retention in our controls compared with those studies described 
above, and is consistent with the 10% prevalence of PIB binding reported by researchers in 
one study (Mintun et al. 2006), where the mean age of non demented subjects was 65.3. 
Compared to controls, our MCI patients with increased PIB retention had significantly raised 
mean levels of cortical PK binding. However, only raised frontal PK uptake survived a 
correction for multiple comparisons. Regional increases in PK binding were detected less 
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frequently than raised PIB binding in our MCI patients and there are a number of possible 
explanations for this: First, the specific signal associated with 11C-(R)-PK11195 uptake is low 
compared with 11C-PIB uptake, in part reflecting the lower density of activated microglia 
compared with amyloid plaques seen in AD (Nagele et al. 2004). Second, there is a higher 
background non-specific signal seen with PK compared to that seen with 11C-PIB. This may 
have resulted in false negative findings in some patients. Third, when delineating ROIs, we 
used a probabilistic atlas that takes into account variations in individual brain structures. 
However, a limitation of this study is that we did not formally perform partial volume 
corrections for atrophy, which may have resulted in an underestimation of cortical PK 
binding and false negative findings. Against this, however, is that we detected increased 
binding in the anterior and posterior cingulate, relatively small structures compared to our 
other interrogated ROIs. Lastly, we did not determine the APOE4 genotype status in our 
subjects. Evidence exists that APOE4 status may influence reactivity of microglia within 
brain (Lombardi et al. 1998; Mittelbronn et al. 2001).  
An early 11C-PK11195 PET study in AD patients that used a lower sensitivity camera failed 
to detect increased binding in dementia compared to controls (Groom et al. 1995). However, 
there are a number of important methodological differences between that and the present 
study: First, they used a cerebellar reference region although specific binding of PK may be 
found here. This could have masked increased binding in other brain areas. Second, their 
control group consisted predominantly of patients with small cerebral gliomas which can bind 
PK. Thirdly, they used racemic PK11195 whereas we used the active (R)-enantiomer of 
PK11195 which has been shown to bind PK binding sites with nanomolar affinity (Shah et al. 
1994). More recently, SPECT (Versijpt et al. 2003) and PET (Edison et al. 2008a) studies in 
AD patients have demonstrated significant increases in cortical PK binding, confirming this 
tracer is capable of detecting microglial activation in vivo in dementia. Our PK control group 
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was younger (mean age 60.2±9.3) than our PIB positive MCI group (mean age 69.1 ±6.4). 
Microglial activation has been reported to occur with ageing (DiPatre and Gelman 1997) 
which may have contributed to our findings of increased PK binding in our controls. 
However, statistical analysis of both our PIB and PK data was adjusted for age in an effort to 
minimise any such age-related effects.     
At the time of performing this study, only one study had reported the use of 11C-(R)-PK11195 
in MCI patients (Cagnin et al. 2001). This PET study focused primarily on AD patients, but 
did include one patient with isolated memory impairment who demonstrated increased 
binding in sub-regions of the temporal lobe. As 18F-FDG PET was normal at this time, this 
report is evidence that microglial activation can occur before metabolic deficits become 
evident. This viewpoint is supported up by a histopathological study in AD subjects (Arends 
et al. 2000) where microglial activation along with Aβ and congophilic deposits were found 
in the middle frontal gyrus in the absence of neurofibrillary tangles. It is intraneuronal tangles 
that result in reduced neuronal firing and metabolism in AD.  These observations provide a 
rationale for assessing microglial activation in MCI patients, some of whom will have 
amyloid deposition at the time of clinical presentation.  
We found no correlation between individual levels of amyloid deposition, as measured by 
11C-PIB PET, and microglial activation, as assessed by 11C-(R)-PK11195 PET. This is in 
contrast to immunohistochemistry studies which have found activated microglial cells 
clustered at sites of neuritic plaques. However, it has also been demonstrated that not all 
amyloid plaques are associated with surrounding microglia (Streit 2005), again implying that 
multiple factors may be involved in microglial activation as a response to amyloid pathology. 
Furthermore, two of our MCI subjects who demonstrated increased PK binding had normal 
PIB uptake, consistent with the notion that microglia activation is a non-selective response to 
neuronal damage that may occur irrespective of the cause of injury. The first subject, (MCI-
 71 
14) was a 70 year-old woman, who had small focal increases in PK binding in the frontal and 
parietal cortices. In the five years following the onset of her symptoms she had shown no 
progression, supported by annual clinical, neuropsychological and neuroimaging 
assessments. Her underlying diagnosis and cause for PK findings remain unclear, although 
her clinical stability over this time period does not suggest a neurodegenerative cause for her 
memory impairment. The second patient (MCI-10), who had increased PK binding in all 
cortical regions of interest, was a 74 year-old man with a history of memory impairment 
dating back at least five years. This was associated with ventricular enlargement on MRI but 
annual clinical and neuropsychological assessments showed no convincing progression over 
this time. Subsequently he suffered a sub-acute deterioration in his cognition associated with 
further increasing ventricular enlargement and so a ventriculoperitoneal shunt was inserted 
which led to an improvement in his symptoms. An underlying neurodegenerative condition, 
again, seems unlikely given the long period of stability in his symptoms.  
Finally, no correlation was found between MMSE scores or disease duration with PIB 
retention and PK binding in our PIB-positive subgroup. It is likely, however, that MMSE and 
other neuropsychometry measures in these MCI patients are influenced by additional 
pathology apart from Aβ such as the presence or absence of neurofibrillary tangles. 
Consistent with this comment is the observation that the only significant correlations between 
MMSE scores and PK binding were found in our PIB-negative subgroup, where lower 
MMSE scores correlated with higher 11C-(R)-PK11195 binding in the anterior cingulate and 
temporal cortex. The recent development of higher affinity PET radioligands which bind to 
the TSPO, such as 11C-DAA1106 (Venneti et al. 2007) and 11C-vinpocetine (Vas et al. 2008) 
may provide greater sensitivity for assessing and quantifying microglial activation in 
cognitive impairment and allow one to further explore the relationship between microglial 
activation, fibrillar amyloid and cognition.  
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4. Conversion of amyloid positive and negative MCI to AD over 3 
years 
 
4.1. Introduction 
The overall rate of progression for an aMCI patient to a clinical diagnosis of AD is typically 
10-15% per year (Petersen et al. 2001; Boyle et al. 2006), with total conversion rates to 
dementia being reported as high as 80% at six year follow-up (Petersen 2004). However, 
aMCI individuals comprise a heterogeneous group of patients, not all of whom will progress 
to dementia- some may even recover. Longitudinal studies have therefore focused on 
identifying predictive biomarkers of conversion to AD. Such studies have shown impaired 
performance on neuropsychological measures such as delayed recall from the Rey Auditory 
Verbal Learning Test (Tierney et al. 1996) to be sensitive and specific for predicting those 
most likely to develop AD. Structural and functional neuroimaging measures such as 
hippocampal atrophy and lower temporoparietal glucose uptake respectively, (Jack et al. 
1999; Chetelat et al. 2003) have also been reported to be of predictive value in assessing risk 
of conversion, as have non-imaging biomarkers such as CSF amyloid and tau levels 
(Bouwman et al. 2007) and carriage of the APOE ε4 allele (Aggarwal et al. 2005). Low levels 
of CSF Aβ42 correlate with Aβ neuropathology at autopsy (Strozyk et al. 2003), and in 
studies combining CSF and PIB PET, nearly 100% concordance is present between the two 
biomarkers (Fagan et al. 2006). However, none of these potential biomarkers for conversion 
from MCI to AD account alone for the actual rate of conversion.  
In view of the 50% incidence of AD type pathology in subjects with MCI, it follows that any 
in vivo marker of amyloid could potentially be a candidate for predicting disease progression. 
However, although neuropathological studies on post-mortem brain tissue consistently report 
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this increased prevalence of AD pathology, a difficulty with autopsy studies in MCI is that 
inevitably no longitudinal outcome data are available. PET now provides an opportunity to 
correlate in vivo the presence of increased brain amyloid load in health and MCI with clinical 
outcome. The aim of this PET study was to determine the rates at which aMCI subjects with 
and without an increased amyloid load convert to clinically probable AD over a one to three 
year window. The brain amyloid loads between PIB-positive MCI subjects who converted to 
AD at faster and slower rates were also compared.  
 
4.2. Methods 
4.2.1. Subjects 
4.2.1.1. MCI subjects   
Thirty one subjects fulfilling Petersen’s criteria for amnestic MCI were studied. Fourteen of 
these MCI subjects (mean age 66.6 years: SD 9.6) were recruited from UK Hospitals 
(Imperial College Healthcare NHS Trust, The National Hospital for Neurology and 
Neurosurgery, St. Margaret’s Hospital and Victoria Hospital). The remaining 17 subjects 
(mean age 71.7 years: SD 5.3) were recruited from and scanned at the University Hospital of 
Turku, Finland. Table 4.1 displays the demographic data of MCI subjects and controls 
according to centre. The majority of MCI subjects enrolled to the study were newly 
diagnosed cases. The clinical criteria for MCI were (1) subjective memory complaint by the 
patient preferably corroborated by an informant, (2) objective memory impairment as 
assessed by performance below age-matched normals on at least one neuropsychological 
measure of memory, (3) normal performance in other cognitive domains, (4) intact activities 
of daily living and (5) not demented. Again, a strict cut-off score was not applied for the 
definition of objective memory impairment. However, the appropriate age-matched 
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normative values were used when determining evidence for objective memory impairment on 
performance on tests of memory.    
4.2.1.2. Controls 
11C-PIB PET data for our MCI cohort were compared with those of twenty-six age-matched 
controls. Fourteen controls were from London (mean age 64.6 years: SD 6.3) and 12 from 
Turku (mean age 66.2 years: SD 6.8) (Edison et al. 2008b). The controls were healthy 
volunteers without any history or evidence of neurological or psychiatric disease. All 
underwent detailed clinical examination and had no evidence of memory impairment on 
neuropsychological testing. Informed written consent was obtained from all participating 
subjects and ethical approval was obtained from the Ethics Committees of Hammersmith and 
Queen Charlotte’s Hospitals and the Southwest Finland Health Care District.  
 
 
Table 4.1 Demographic details of MCI patients according to centre 
 Controls 
(n=26) 
MCI 
(n=31) 
 London Turku London Turku 
Total number 14 12 14 17 
Mean age (years±SD) 64.6±6.3 66.2±6.8 66.6±9.6 71.7±5.3 
Male/Total 8/14 3/12 9/14 10/17 
Mean MMSE at baseline (±SD) 29.9±0.3 29±0.9 27.7±1.5 27.4±1.5 
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4.2.2. Clinical assessment 
All MCI subjects had a neurological examination, neuropsychological assessment, and 
routine blood analysis. Additionally, APOE ε4 status was available in 17 of our 31 MCI 
subjects (the Turku cohort). 
4.2.2.1. Neuropsychometry tests 
The neuropsychometry tests for memory included the Wechsler Memory Scale-Revised 
(WMS-R) (Wechsler 1987), the ADAS word list learning with delayed recall (Rosen et al. 
1984), the California Verbal Learning Test (CVLT) (Delis et al. 1987), the immediate and 
delayed recall of a modified complex figure (Becker et al. 1987) and the word list savings 
(%) of the Consortium to Establish a Registry for Alzheimer’s Disease (CERAD) test battery 
(Morris et al. 1988). The word list savings is the percentage of words correctly retrieved on 
the delayed recall of ten words, compared to the number of words immediately recalled 
during the last (of three) learning trials of the same ten words.      
4.2.2.2. Clinical follow-up  
Each MCI subject was clinically followed for one to three years after their baseline 11C-PIB 
PET scan. Over this follow-up period, there was either no change in their diagnosis and they 
still fulfilled criteria for MCI (non-converters), or their symptoms and clinical performance 
declined to the extent that they fulfilled NINCDS-ADRDA criteria (McKhann et al. 1984) for 
a diagnosis of probable AD (converters). Patients underwent detailed clinical and 
neuropsychological assessment, by both a senior physician (consultant neurologist or 
consultant psychiatrist) and neuropsychologist respectively, at least once at each year of 
clinical follow-up. The final clinical diagnosis of each subject at this time was given by the 
consultant as either MCI or AD.  Those MCI subjects who converted to AD during the follow 
up period were further categorised into two groups according to their speed of conversion. 
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The PIB-positive faster converters clinically converted to AD within one year follow-up and 
the PIB-positive slower converters converted to AD after more than one year. 
   
4.2.3. MRI scanning 
All subjects had T1-weighted volumetric MRI to allow structure-function co-registration with 
11C-PIB PET images. Additionally, T2-weighted MRI was performed to exclude structural 
lesions or significant white matter disease.  
 
4.2.4. PET scanning 
Permission to administer 11C-PIB was obtained from the ARSAC in the UK, and the Finnish 
National Agency for Medicines.  
MRI data for these studies was collected personally, and by P. Edison, H. Archer and J. 
Koivunen, clinical research fellows also involved in the study. 11C-PIB PET data for this 
study was collected personally and by P. Edison. 
4.2.4.1. 11C-PIB 
UK: All MCI subjects and healthy volunteers were scanned at the Cyclotron Building 
Hammersmith Hospital, London using a Siemens ECAT EXACT HR+ camera (Siemens 962, 
Knoxville, TN) in 3 dimensional acquisition mode. 11C-PIB was manufactured and supplied 
by GE Healthcare, Hammersmith Imanet, UK and subjects received a mean dose of 367 ± 25 
MBq injected intravenously over 30 seconds. Prior to the injection of 11C-PIB, a 10-minute 
transmission scan was performed to measure tissue attenuation of 511 keV γ-radiation, which 
was immediately followed by a 90-minute dynamic emission scan, collected as 32 time 
frames.  
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 Turku: MCI subjects and healthy volunteers were scanned with a GE Advance PET camera 
(GE Medical Systems, Milwaukee, WI) and the dynamic PET emission scans were acquired 
in 3 dimensional mode. An 8-minute transmission scan with 68Ge rod sources was performed 
prior to the injection of 11C- PIB to measure tissue attenuation of 511 keV γ-radiation. 11C-
PIB was manufactured by Turku PET Centre, Finland and the mean injected dose of 11C-PIB 
for MCI subjects was 487 ± 44 MBq. This was followed by a 90-minute dynamic emission 
scan, collected as 28 time frames; the sequence of the scan consisted of 4 x 30-second frames, 
9 x 1-minute frames, 3 x 3-minute frames, 10 x 5-minute frames and 2 x 10-minute frames. 
Imaging data was reconstructed using standard software.  
 
4.2.5. Data processing and analysis  
4.2.5.1. Creation of 11C-PIB target region: cerebellar cortex ratio images  
All UK and Turku PIB PET images were personally analysed at the Cyclotron Building 
Hammersmith Hospital, London. As described in detail in the previous chapter, using the 
cerebellar cortex as a reference region for non-specific tracer binding, parametric ratio 
images of PIB retention were created by normalizing the 60 to 90-minute (late) summation 
images to the mean cerebellar cortical uptake value over this same period. Image analysis 
was performed using Analyze and SPM99. Using individual T1-weighted MRIs as a 
template, each parametric image was normalized into MNI space and PIB retention assessed 
by both ROI analysis and SPM analysis.  
4.2.5.2. Statistical analysis 
1. ROI analysis 
Using the probabilistic atlas to create an individualized anatomical template for each subject, 
average PIB retention (left and right) was quantified in the anterior cingulate, posterior 
cingulate, frontal, temporal, parietal and occipital cortex. Individually, PIB retention ratio 
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values for each MCI subject were compared to the control means of their scanning site 
(London or Turku). PIB binding was considered increased in individual MCI subjects if ratio 
values were at least 2 SD above the control mean in our six predefined ROIs. Increases in 
PIB retention in the MCI subjects relative to their control mean were described in two ways, 
the first being as a percentage change calculated using the formula below;  
 
 
Percentage change in ratio value = (Rs - Rcm)*100 
                   Rcm 
 
(where Rs =  ratio value for individual MCI subject, Rcm = control mean of the 
corresponding scanning site).  
 
 
Additionally, univariate analysis of variance was used to detect significant differences in 
regional PIB binding between MCI and control groups, with the two different PET centres 
being set as fixed factors, and using the P plot method (Turkheimer et al. 2001) and 
Hochberg correction to control for multiple comparisons. Using these methods, PIB retention 
was also compared between MCI converters and non-converters. Lastly, differences in 
regional PIB binding was compared in the PIB positive subjects alone; that in the PIB-
positive faster converters against that in the combined group of PIB-positive slower 
converters and PIB-positive non-converters (no conversion to date). A secondary statistical 
analysis was performed using age as a covariate, the rest of the analysis being otherwise 
identical. 
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For the 17 MCI subjects from Turku where the APOE  ε4 genotype status was known, 
binomial Chi-Square tests were applied to assess the relationship between APOE ε4 status 
and rates of conversion. Statistical tests were performed using SPSS for Windows 14.0 
statistical software. 
 2. Statistical parametric mapping (SPM): 
In addition to ROI analysis, PIB ratio images were also interrogated with SPM in order to 
localise at a voxel level, clusters of significant differences in mean PIB retention between 
MCI converters and non-converters, and between PIB-positive faster and PIB-positive slower 
and non-converters. 
SPM is a voxel- based statistical package. However, before one can make inferences about 
regionally specific effects in the brain, the images must first be spatially transformed into a 
standardised space (here they are normalised to MNI space). This is followed by smoothing 
to reduce the effects of high frequency variation in the data and improve the signal: noise 
ratio. By the central limit theorem, smoothing the data will render the errors more normal in 
their distribution which in turn ensures the validity of inferences based on parametric tests 
applied to the data. Smoothing can be achieved by either replacing the values of each 
individual pixel within a given area by the mean of all values within this area, or by 
convolving voxel data with a Gaussian kernal which defines the form of the function used to 
compute the weighted average of each point in relation with its neighbours. We used the 
latter approach, and smoothed our normalized PIB ratio images using a Gaussian kernel of 
six mm.  
The general linear model is then applied to each independent voxel of the smoothed data; 
interrogations may range from simple unpaired t-tests to multifactorial ANCOVAs.  The 
resulting statistical parameters are then presented, in the simplest form as a table which 
displays the coordinates of clusters of voxels that show the most significant differences in 
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activity between conditions, each with an associated t statistic (from which a z-score is 
derived), and a p value that can be considered corrected for the volume of brain tested. This 
output may be further manipulated using various image templates associated with a colour 
map whose gradient is mapped to statistical values, allowing the location of voxels that have 
shown any significant differences in brain activity between conditions to be visualised. By 
specifying different contrasts one can test for a variety of effects, with the output set at 
different thresholds to detect significance. In our case, between-group comparisons were 
made using a voxel threshold of p<0.0001 (converters vs. non-converters) and p<0.01 (faster 
converters vs. slower and non-converters), with an extent threshold of 200 voxels. Grand 
mean or proportional scaling was not applied to this data, and the two scanning sites were 
considered as covariates when performing the analysis. Any resulting clusters with a 
corrected p-value of <0.05 are reported.    
 
Further considerations with methodology: 
Both MCI subjects and control groups from the two scanning centres (London and Turku) 
were well matched for age, with no significance difference detected between either of the 
groups compared by centre. However, the PET scanners used by the two sites were different. 
Therefore a number of measures were taken when analysing the data to try to minimise any 
potential variance introduced by the different sites. First, all PIB PET dynamic data was 
acquired over 90-minutes and expressed as a 60 to 90-minute target region: cerebellar ratio of 
PIB retention, so minimising between-site variability by using an internal reference for each 
subject. Furthermore, increases in PIB retention in the MCI subjects were expressed relative 
to control means for that site as a percentage change. Second, all scans were analysed 
personally at the Cyclotron Building Hammersmith Hospital, thus removing any potential 
inter-observer variation. When using univariate analysis of variance to detect significant 
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differences in regional PIB binding (obtained by ROI analysis) between MCI and control 
groups, we controlled for the difference in PET centres (i.e. the categorical independent 
variables), by setting them as fixed factors in our model. Lastly, when performing SPM 
analysis, we controlled for any variance introduced by the different scanning sites by setting 
them as covariates. 
 
4.3. Results 
4.3.1 ROI analysis 
4.3.1.1. Baseline 
Individually, 17 of 31 (55%) MCI subjects had significantly increased PIB retention values 
compared to controls at baseline in all regions of interest. Two other MCI subjects 
demonstrated isolated increases in PIB retention in the anterior cingulate and frontal cortex 
(MCI-2-T and MCI-7-T). Individual PIB retention values in the 17 MCI subjects from Turku 
are provided in Appendix 4 (those from London have been provided in Appendix 1). 
When compared to controls, the MCI subjects showed a 41% increase in PIB retention in the 
anterior cingulate (p<0.01), 40% increase in the posterior cingulate (p<0.01), 37% increase in 
the frontal cortex (p<0.01), 36% increase in the parietal cortex (p<0.01), 28% increase in the 
temporal cortex (p<0.01) and 20% increase in the occipital cortex (p<0.01). These 
significance levels remained unchanged after applying age as a covariate. The mean PIB 
retention ratio values in the MCI subjects are shown in Table 4.2. 
4.3.1.2. Follow-up 
During a 12-36 month follow-up period after their baseline PIB PET scan, 15 (4 London, 11 
Turku) of the 31 MCI subjects (48%) clinically converted to AD. Fourteen of these 15 
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converters were PIB-positive at baseline, making the percentage conversion rate in the PIB-
positive subgroup 82% (14 of 17) over this same follow-up period. One converter had small 
increases in PIB retention in the anterior cingulate and frontal cortex alone. When assessed 
by centre, the percentage conversion rate in the PIB-positive subgroup was 57% for London 
(4 out of 7) and 100% for Turku (where all ten PIB-positive MCI subjects converted to AD). 
 
MCI converters versus non-converters: The converters showed higher PIB retention in all 
cortical brain regions (p<0.01 both with and without correction for age) compared to the non-
converters (Table 4.2).   
 
MCI PIB-positive faster versus combined PIB-positive slower and non-converters: As a 
group, the PIB-positive faster converters had higher PIB retention values compared to the 
combined subgroup of slower and non-converters in the anterior cingulate (p= 0.027) and 
frontal cortex (p= 0.031), although this did not survive correction for multiple comparisons 
(Table 4.3). Figure 4.1 illustrates individual ratio values in PIB-positive faster, slower and 
non-converting MCI subjects compared to controls. In total, eight (47%) of the 17 PIB-
positive MCI subjects were faster converters, having converted to a diagnosis of clinically 
probable AD within one year of follow-up after their baseline 11C-PIB PET scan.    
 
APOE ε4 status:  An APOE ε4 allele was present in 41% (7 out of 17) of the MCI subjects in 
whom the APOE ε4 status was known. Six of these 7 APOE ε4 carriers were PIB-positive. 
There was an association between APOE ε4 status in the PIB-positive MCI subjects and rate 
of conversion, with all four of the faster converters with known genotype (100%) being 
APOE ε4 carriers (p= 0.035; Pearson Chi-Square).  Two out of six (one-third) of the PIB-
positive slow converters were APOE ε4 carriers.    
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Table 4.2 Demographic data and 11C-PIB mean retention ratio values in MCI subgroups   
 MCI  
 
    MCI  
converters  
MCI non-
converters 
Controls  p 
value 
Total number 31 15 16 26 _ 
Age (years) 69.4±7.9 71±6.3 67.9±9.0 65.3±6.5 NS 
Male/Total 19/31 9/15 10/16 11/26 _ 
MMSE at baseline  27.5±1.5 27.1±1.5 27.9±1.3 29.5±0.8 NS 
PIB retention Ratio      
     Anterior cingulate 1.61±0.49 1.98±0.37 1.26±0.28 1.13±0.08 <0.01* 
     Posterior cingulate 1.68±0.54 2.10±0.41 1.30±0.32 1.19±0.13 <0.01* 
     Frontal 1.50±0.43 1.82±0.36 1.20±0.23 1.09±0.06 <0.01* 
     Temporal 1.40±0.38 1.66±0.36 1.16±0.18 1.09±0.06 <0.01* 
     Parietal 1.51±0.44 1.82±0.38 1.21±0.24 1.10±0.07 <0.01* 
     Occipital 1.37±0.33 1.59±0.35 1.17±0.11 1.14±0.07 <0.01* 
Values = mean ± SD; NS = No significance between MCI converters compared to  
MCI non-converters: (2-tailed independent samples t-test).  
p value: * Statistical significance in PIB retention ratio values between MCI converters 
compared to MCI non-converters: (univariate analysis of variance). 
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Table 4.3 Demographic data and 11C-PIB mean retention ratio values in PIB-positive MCI 
subgroups.   
 PIB-positive faster 
converters  (n=8) 
PIB-positive slower 
converters (n=6) 
and non-converters 
(n=3) 
p value p value‡ 
 
Total number 8 9 _ _ 
Age (years) 71.5±7.1 70.6±5.3 NS _ 
Male/Total 4/8 6/9 _ _ 
MMSE at baseline 27.0±1.5 27.7±1.7 NS _ 
PIB retention Ratio     
   Anterior cingulate 2.17±0.38 1.82±0.11 0.03 0.04‡ 
    Posterior cingulate 2.25±0.42 1.98±0.21 0.13 0.15 
    Frontal 2.01±0.39 1.65±0.12 0.03 0.04‡ 
    Temporal 1.83±0.40 1.51±0.17 0.07 0.09 
    Parietal 1.95±0.42 1.71±0.20 0.18 0.23 
    Occipital 1.67±0.45 1.47±0.18 0.26 0.33 
NS = No significance between MCI converters compared to MCI slower and non-converters 
(2-tailed independent samples t-test).  
p value relates to PIB-positive MCI faster-converters compared to PIB-positive MCI slower-
converters: (univariate analysis of variance). p value‡ (age as covariate) is significant. 
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Figure 4-1 Scatter-plot showing the distribution of individual PIB retention values in PIB-
positive MCI subgroups: faster, slower and non-converters compared to controls (top line = 
Turku control mean, bottom line = London control mean). 
 
 
 
 
4.3.2. SPM findings: 
 MCI converters versus non-converters:  
SPM detected significantly higher 11C-PIB uptake in the MCI converters compared to non-
converters in the anterior and posterior cingulate, frontal, temporal and parietal cortices, with 
local maxima in the frontal cortex bilaterally, as illustrated in Figure 4.2.   
 
 86 
Figure 4-2 SPM analysis: areas of significantly increased 11C-PIB retention in MCI 
converters compared to MCI non-converters. (Corrected p-value at cluster level <0.001).  
 
 
 
 
 
MCI PIB-positive faster converters versus combined PIB-positive slower and non-converters: 
SPM confirmed ROI analysis findings of significantly higher PIB binding in the PIB-positive 
faster converters compared to the combined group of PIB-positive slower and non-converters. 
This was most marked in the superior frontal cortex. SPM additionally localised significantly 
increased 11C-PIB binding in the temporal cortex of faster compared to slower and non-
converters, as illustrated in Figure 4.3.  
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Figure 4-3 Sagittal (A) and coronal sections (B and C) illustrating increased 11C-PIB 
retention in anterior cingulate, frontal and temporal cortex in the PIB-positive MCI faster 
compared to PIB-positive slower and non-converters. (Corrected p-value at cluster level 
<0.001). 
 
 
 
 
4.4. Discussion 
In this study, 17 of 31 (55%) subjects with aMCI had significantly increased PIB retention 
compared to controls. When compared to non-converters, MCI converters were found to have 
significantly increased PIB retention in all designated regions of interest. Individually, 48% 
of the aMCI subjects (15 of 31) converted to a diagnosis of AD during the follow-up period 
which ranged from one to three years (2.9 years ± 0.5 in converters; 2.5 years ± 0.7 in non-
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converters). Fourteen of these 15 subjects were PIB-positive at baseline, making the 
percentage conversion rate in the PIB-positive subgroup 82% (14 of 17) over this same 
follow-up period. A recent PET study (Forsberg et al. 2008) reported that one third of their 21 
MCI subjects, all PIB positive, converted to AD over eight months. Only 12 of 21 of their 
subjects with MCI were categorised as amnestic, but all seven converters were of the 
amnestic subtype. The conversion rate to AD in PIB-positive compared to PIB-negative MCI 
subjects in these two studies suggests that in vivo detection of amyloid deposition may 
provide useful prognostic information with respect to stratifying those amnestic MCI patients 
at increased risk of dementia. Of interest, none of our MCI subjects reverted back to normal 
cognition during their follow-up period.  
In a longitudinal 11C-PIB PET study of early AD patients over two years (Engler et al. 2006), 
researchers found that the amyloid load in their AD group remained stable. This suggests that 
amyloid deposition occurs early in the clinical evolution of AD. Such a viewpoint is 
supported by PIB PET findings in asymptomatic mutation carriers of the PSEN1 gene (Klunk 
et al. 2007; Koivunen et al. 2008) and duplication of the APP locus (Remes et al. 2008) 
where raised striatal 11C-PIB uptake can be seen.  It is less clear, however, at what stage 
amyloid deposition, as detectable by PIB PET, plateaus in any given patient during their 
clinical transition from MCI to AD. We found that our PIB-positive more rapid converters 
had a significantly increased amyloid burden in the anterior cingulate and frontal cortices that 
fell within the reported range for AD patients (Edison et al. 2007). The slower converters had 
lower levels of amyloid load and so may represent a ‘prodromal’ AD phase at the time of 
scanning.  
Alternatively, some separate factor, for example APOE status or levels of education 
(Kemppainen et al. 2008), may have influenced the difference in rates of conversion and 
amyloid burden between the two groups. Post-mortem studies have shown correlations 
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between the presence of an APOE ε4 allele and higher Aβ burden in the brains of sporadic 
AD patients (Schmechel et al. 1993; Rebeck et al. 1993). A separate study found that levels 
of Aβ protein deposition varied according to APOE genotype in elderly subjects both with 
and without dementia, the highest mean values being associated with the presence of at least 
one ε4 allele (Grimmer et al. 2008). A limitation of this current study is that we did not 
possess APOE ε4 status in all of our subjects with MCI. A previous 11C-PIB PET study in 
AD, examining the association between clinical severity and amyloid plaque load, reported 
APOE ε4 status to be a possible confounding factor (Pike et al. 2007). Here, they found an 
association between dementia severity and 11C-PIB uptake in AD, ROI analysis showing that 
more severely demented individuals had higher 11C-PIB uptake bilaterally in the frontal and 
anterior cingulate cortices and putamina. In our cohort we found an association between 
APOE ε4 status in our PIB-positive MCIs and rate of clinical conversion to AD, with all 
faster converters being APOE ε4 carriers. 
At the time of clinical follow-up, the clinicians involved in the diagnosis of MCI subjects 
converting to AD were not blinded to the results of their baseline 11C-PIB PET data. This 
may have influenced the diagnosis of the MCI subjects either towards or away from that of 
conversion to AD. Against this however, is the fact that although the presence of amyloid in 
MCI patients at presentation may have prognostic implications as discussed previously, the 
clinical diagnosis to probable AD in this study was made according to established NINCDS-
ADRDA criteria (McKhann et al. 1984), which currently does not depend upon the results of 
neuroimaging.  
Lastly, two aMCI subjects showed small selective increases in PIB retention in the anterior 
cingulate and frontal cortex alone. The first was an 80-year old woman, whose clinical 
diagnosis during a three-year follow-up period remained one of MCI, and the second, was a 
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64-year old man who at his three-year follow-up, had clinically converted to AD. Although a 
number of 11C-PIB PET studies have demonstrated increased amyloid deposition in 
asymptomatic elderly controls (Mintun et al. 2006), it is likely that the focally increased 
amyloid burden in our first patient represents ‘preclinical’ AD given her documented memory 
impairment. Further clinical and PIB PET follow-up in this patient will determine the 
significance of this increased amyloid burden, while further PIB PET follow-up in all our 
MCI subjects will allow us to follow, in vivo, the progression over time in amyloid 
deposition and its relevance to the clinical conversion to AD.    
 
 
 
 
 
 
 
 
 91 
5. Longitudinal assessment of amyloid deposition and cerebral 
glucose metabolism in MCI and AD 
 
5.1. Introduction 
A definitive diagnosis of AD requires histological confirmation, which is seldom practical 
during life. Neuropathological studies on post-mortem tissue can confirm the presence of Aβ 
plaques and neurofibrillary tangles in over 80% of clinically probable AD diagnosed 
according to NINCDS-ADRDA criteria and detect such pathology in over 50% of cases with 
amnestic MCI according to Petersen criteria (Petersen et al. 2006). Such studies have 
demonstrated, however, that Aβ plaque density does not correlate well with dementia severity 
when compared to other measures such as synaptic loss and tangle density (Terry et al. 1991). 
A difficulty arises, when one wishes to assess pathological changes longitudinally as a tissue 
diagnosis requires either a brain biopsy or a post-mortem autopsy.  
PET provides us with the opportunity not only to demonstrate in vivo the metabolic and 
neurochemical changes that occur in patients with MCI and dementia at the onset of their 
symptoms, but also to follow these changes over time. This modality can, therefore, help us 
to study the natural time-course of AD pathology and its relation to cognition, and potentially 
allows us to assess in vivo the effectiveness of anti-amyloid and neuroprotective therapies 
purported to affect such measures.   
In the following PET study changes in regional cerebral beta-amyloid deposition and glucose 
metabolism (rCMRGlc) have been compared in MCI and AD patients longitudinally 
followed for a three-year period. Additionally, these measures were correlated with cognitive 
performance in the MCI subjects.  
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5.2. Methods 
5.2.1. Subjects 
5.2.1.1. MCI subjects   
Ten subjects (mean age 66.9 years: SD 7.7) fulfilling Petersen’s criteria for amnestic MCI 
underwent serial 11C-PIB PET as part of this longitudinal study. These MCI patients were all 
recruited from UK Hospitals (Imperial College Healthcare NHS Trust, The National Hospital 
for Neurology and Neurosurgery, St. Margaret’s Hospital and Victoria Hospital) and had 
completed baseline assessments which included a neurological and neuropsychometric 
assessment, 11C-PIB and 18F-FDG PET. MCI patients were eligible for the follow-up study if 
they were 35-79 years of age but excluded if they had significant white matter disease on 
MRI, a recent history of drug or alcohol dependence, any clinically significant major 
psychiatric disorder, previous history of schizophrenia or any medical condition that could 
influence neuropsychological testing. Subjects with any other general contra-indications to 
PET or MRI were also excluded. 
5.2.1.2. AD subjects 
Twelve subjects (mean age 66 years; SD 5.8) meeting the NINCDS-ADRDA criteria for the 
diagnosis of probable AD were also followed longitudinally. All 12 AD subjects had 11C-PIB 
and eight had 18F-FDG PET at baseline. AD subjects were eligible for study if their age-range 
was 55-79 years and the exclusion criteria were similar to those for the MCI subjects. The 
demographic details of the MCI and AD patients are shown in Table 5.1. Informed written 
consent was obtained from all participating AD and MCI subjects. Additionally, all AD 
subjects were required to be accompanied by a carer on at least the first visit when obtaining 
informed consent. Ethical approval for the study was obtained from the Ethics Committees of 
Hammersmith and Queen Charlotte’s Hospitals.  
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Table 5.1 Subject demographics 
Characteristics MCI AD 
Number of subjects 10 12 
Mean age at first 11C-PIB (years ± SD)  66.9 ± 7.7 66 ± 5.8 
Gender: number (%) women  2 (20%) 6 (50%) 
MMSE at baseline, mean ± SD (range)  27.9±1.3 
(26-30) 
21.6 ±3.6 
(15-26) 
MMSE at first follow-up, mean ± SD (range) 26.8±2.5 
(22-30) 
17.6±6.5* 
 (9-25) 
Months between first two 11C-PIB scans, mean ± 
SD (range) 
15.1 ± 2.7 
(12-18) 
18.4 ± 3.0 
(14-22) 
* MMSE unavailable in 2 AD patients at follow-up  
 
 
5.2.2. Follow-up  
5.2.2.1. Neuropsychometry  
The neuropsychometry tests used for follow-up assessments were the MMSE (Folstein et al. 
1975), the ADAS Word List Learning test & 30 minute delayed recall (Rosen et al. 1984), 
WRTM for words and faces, the copy and immediate & delayed recall of a Rey modified 
complex figure (Becker et al. 1987), digit span forwards (Wechsler 1981), Trail Making Part 
A and B (Reitan 1958), 30-item Boston Naming Test (Saxton et al. 2000), Letter fluency 
(FAS) and category fluency (animals, birds and dogs) (Benton 1968) and the digit symbol 
test (Smith 1982). These tests took approximately 90 minutes to administer and were 
completed during one sitting, allowing a short break during the testing session. 
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Neuropsychometry testing, MRI and PET scanning at follow-up were performed personally 
and by P. Edison. 
5.2.2.2. MRI scanning 
At both baseline, and follow-up each patient underwent volumetric T1 (and T2) weighted 
MRIs to allow structure-function co-registration with 11C-PIB and 18F-FDG PET images. The 
MRIs were obtained with either a 1.5 Tesla GE MRI scanner or a 3 Tesla Philips Achieva 
MRI scanner. All MRIs used for co-registration of each subject’s follow-up PET were 
performed with the same scanner as at baseline (1.5 or 3T).  
5.2.2.3. 11C-PIB PET scanning 
After baseline 11C-PIB PET, each MCI and AD subject was followed for a period ranging 
from one to three years, during which time they all underwent repeat 11C-PIB PET. The mean 
interval between baseline and follow-up scans for the MCI subjects was 15.1 ± 2.7 months 
and for the AD subjects, 18.4 ± 3.0 months. Additionally, four MCI and four AD subjects had 
11C-PIB PET on a third occasion. This third scan was performed between 26 to 32 months 
after baseline 11C-PIB PET (mean between scan interval 29.3 ± 2.57 months) for the MCI 
subjects and between 29-36 months after baseline PET (mean between scan interval 32.1±3.2 
months) for the AD subjects.  
 
Scan procedure: Follow-up 11C-PIB PET was performed with the same camera (Siemens 
ECAT EXACT HR+ tomograph) and using the same imaging and data reconstruction 
protocols as at baseline; a 10 minute transmission scan was performed prior to the injection 
of 11C-PIB to measure tissue attenuation of 511 keV γ-radiation, which was followed by a 90- 
minute emission scan. 11C-PIB was manufactured by Hammersmith Imanet at the Cyclotron 
Building and the mean injected 11C-PIB dose for the MCI subjects was 375.33 ± 10.6 MBq at 
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baseline and 360.05 ± 18.9 MBq at first follow-up. The 12 AD subjects received 366.8 ± 
37.24 MBq of 11C-PIB at baseline and 359.5 ± 31.3 MBq at first follow-up.  
5.2.2.4. 18F-FDG PET scanning 
MCI: Of the ten MCI subjects who underwent baseline 18F-FDG scans, only those (five) with 
raised PIB uptake (‘whole brain’:cerebellar PIB retention ratios of greater than 1.5) 
underwent repeat 18F-FDG scans at follow-up (mean scan interval 14.8 ±3.0 months). Two of 
these five PIB positive MCI subjects underwent a third 18F-FDG PET scan during the follow-
up period.  
 
Scan procedure: Follow-up 18F-FDG PET was performed on the same Siemens ECAT 
EXACT HR+ tomograph as baseline 11C-PIB and 18F-FDG scans. After a 10-minute 
transmission scan, 18F-FDG was administered intravenously over 30 seconds. This was 
followed by a 60 minute dynamic emission scan collected as 28 time frames (1 x 30s 
(background counts), 1 x 15s, 1 x 5s, 4 x 10s, 4 x 30s, 4 x 60s, 4 x 120s, 9 x 300s) acquired in 
3D mode with the patient resting, their head positioned parallel to the orbitomeatal line and 
their eyes closed in a quiet, dimly lit room. Patients fasted for four hours prior to 18F-FDG 
PET and radial arterial cannulation was performed before injection of the tracer to enable 
rapid blood sampling during the scanning period - a plasma input function is required in order 
to quantitate rates of glucose metabolism. Arterial blood was sampled continuously for the 
first 15 minutes of scanning and then nine additional discrete blood samples of 5mls were 
taken at 5, 10, 15, 20, 30, 40, 50 and 60 minutes. The mean injected dose of 18F-FDG at 
baseline for the MCI group was 193.12 ± 6.64 MBq and at follow-up 187.30 ± 10.94 MBq. 
 
AD: Eight of the 12 AD subjects who had baseline 11C-PIB PET also had baseline 18F-FDG 
PET and, of these, six underwent follow-up 18
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None of these AD patients underwent a third 18F- FDG PET scan. The mean injected dose of 
18F-FDG of the six AD subjects was 188.48 ±7.67 MBq at baseline and 185.55 ± 7.14 at 
follow-up. The radiochemical synthesis of 18F-FDG was performed by Hammersmith Imanet, 
at the Cyclotron Building, Hammersmith Hospital, or Amersham Place, UK. Permission to 
administer both 18F-FDG and 11C-PIB was obtained from the ARSAC UK. 
 
5.2.3. Data processing and analysis  
5.2.3.1. Creation of 11C-PIB target region: cerebellar cortex ratio images  
Summated 11C-PIB images of activity 60 to 90 minutes after tracer injection were created in 
Matlab. Each MRI (re-orientated along the AC-PC line) was then segmented in SPM2 into 
grey matter, white matter and CSF images. This was followed by co-registration of the PET 
images to each subject’s T1 MRI and then by normalisation of the co-registered images into 
MNI stereotaxic space. Using each subject’s anatomical atlas (created by convolving 
binarised grey matter map with a probabilistic brain atlas), activity of 11C-PIB in the 
cerebellar cortex over 60 to 90 minutes was sampled. Finally, target region: cerebellar cortex 
ratio images ratio images were created by dividing the summated images (in standardised 
MNI space) by the mean cortical cerebellar concentration value.  
5.2.3.2. Creation of parametric rCMRGlc images 
After transport into the brain via a passive carrier, D-glucose is first phosphorylated to 
glucose-6-phosphate by hexokinase before entering the glycolytic pathway. 2-fluoro-2-
deoxy-D-glucose (FDG) is a glucose analogue that competes with glucose for both facilitated 
transport across the BBB and then phosphorylation by hexokinase, resulting in its conversion 
to FDG-6-phosphate. Unlike glucose-6-phosphate, FDG-6-phosphate cannot be further 
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metabolised and has low membrane permeability and so is essentially trapped within brain 
tissue for the period of PET, making it a useful marker of local tissue metabolic activity.  
Both compartmental modelling of brain time activity curves and the multiple-time graphical 
analysis technique (MTGA) (Patlak et al. 1983) have been previously used to compute 
rCMRGlc values from 18F-FDG PET. In this study, parametric images of absolute cerebral 
glucose metabolism at a voxel level were generated using spectral analysis. Unlike 
compartmental modelling, spectral analysis does not make prior assumptions about the 
number of kinetic compartments present in brain tissue. Rather, using a plasma input 
function, a spectrum of kinetic components that describe the tissue response to this input is 
derived. One of these kinetic components is the influx constant Ki. Taking the assigned 
computed voxel Ki values, an assigned lumped constant (0.48) (to correct for the faster BBB 
transport and slower phosphorylation of FDG relative to glucose), and measured plasma 
glucose concentrations obtained at specific time points as further inputs, a parametric map of 
rCMRGlc (mmol/L/min) is created. 
The parametric map (rCMRGlc) along with the summated 18F-FDG images of activity 35.5 to 
60.5 minutes after tracer injection was co-registered with each patient’s MRI scan and then 
transformed into MNI space. As with 11C-PIB PET an object map for sampling brain regions 
was created using our in-house probabilistic atlas. However, in the case of FDG, this atlas 
was convolved with the binarised image of both grey and white matter combined. 
5.2.3.3. Statistical analysis 
 ROI analysis: 
For each subject average PIB retention (left and right) was quantified in the anterior 
cingulate, posterior cingulate, thalamus, frontal, temporal, parietal and occipital cortex. PIB 
retention was also quantified in the brainstem, and whole brain (cortical and subcortical grey 
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matter- excluding cerebellum). The same regions were used to quantify rCMRGlc (left and 
right), however as mentioned previously, glucose metabolism in both the grey and white 
matter combined was quantified in these regions.  
Statistical tests were performed using IBM SPSS statistics 19 software. Differences between 
11C-PIB retention and glucose metabolism in the AD and MCI subjects at baseline compared 
to follow-up were calculated using the Wilcoxin matched-Pair Signed-Rank-sum test without 
correcting for multiple comparisons. Individual and group changes in PIB retention and 
cerebral glucose metabolism from baseline to follow-up were also described as a percentage 
change calculated as;  
 
 
Percentage change in value = (Vf - Vb)*100 
     Vb 
 (where Vf  =  value at follow-up, Vb =  value at baseline 
 
 
Correlations between 11C- PIB retention ratios and neuropsychometry performance at follow-
up in MCI subjects were assessed using Spearman’s rank correlation.  
 
5.3. Results 
5.3.1. MCI subjects 
5.3.1.1. Cognition, 11C-PIB binding and glucose metabolism  
1. Cognition: During the first follow-up period, there was a non-significant decrease (p=0.25) 
in mean MMSE of 1.1 point. During this follow-up period, three of the ten MCI subjects 
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clinically converted to a diagnosis of AD. The average neuropsychometry scores for the MCI 
subjects at follow-up are detailed in table 5.2.  
2. Progression of PIB uptake: One of the ten MCI subjects (PIB-positive 73 year old man) 
who underwent follow up 11C-PIB PET was excluded from further PIB analysis as excessive 
head and body movement resulted in poor co-registration of 11C-PIB PET and MRI scans. 
Therefore the following PIB results (and statistical analysis) reported are for the nine 
remaining MCI subjects. At baseline, five subjects were PIB positive and four were PIB 
negative. Classification into PIB positive and negative did not change during the follow-up 
period, although three of the PIB positive subjects clinically converted to AD during this 
time. The mean whole brain 11C-PIB uptake ratio for the MCI group at baseline was 1.51 ± 
0.46, and 1.59 ± 0.52 at first follow-up, representing a 5.6% increase relative to baseline 
which was statistically significant (p= 0.02). The largest percentage increase in 11C-PIB 
retention was observed in the posterior cingulate (6.9%: p= 0.01) followed by 6.1% in the 
frontal cortex (p= 0.02), 5.9% (p=0.02) in the parietal cortex, 5.5% in the anterior cingulate 
(p= 0.07) and 5.4% in the temporal cortex (p= 0.01). Smaller increases were seen in the 
thalamus (3.1%; p=0.27), striatum (4.3%: p=0.07) and brainstem (2.32%: p= 0.37). Mean 
values of cortical 11C-PIB retention at baseline and follow-up in the MCI patients are shown 
in table 5.3. There was a significant difference in standardised uptake value (SUV) in the 
cerebellar cortex of the MCI subjects at baseline and follow-up (p=0.02) (see discussion).  
Lower scores on delayed word recall, and the copy and immediate recall of a Rey modified 
complex figure correlated with higher 11C-PIB binding in several cortical regions at follow-
up (Table 5.4).  
Overall, four MCI subjects underwent a third 11C-PIB PET scan - two PIB-positive and two 
PIB-negative. Of the two PIB-positive subjects, the first was a 64 year-old man who 
underwent a repeat 11C-PIB PET 12 months after his first follow-up scan. During this time 
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there were further regional increases in 11C-PIB uptake ranging from a 4% increase in the 
striatum to a 10% increase in the parietal cortex. Overall, in the 30 months from baseline to 
this final follow-up, he demonstrated an increase in whole brain cortical PIB of 19.5%. His 
diagnosis during this time remained one of MCI. The 11C-PIB PET images for this subject are 
displayed in Figure 5.1. The second patient, a 59 year-old woman demonstrated further 
increases (ranging from 8-16%) in 11C-PIB uptake after the first follow-up scan. When 
compared to uptake at baseline, 27 months previously, whole brain cortical PIB uptake had 
increased by 18%. In contrast, the two PIB negative MCI subjects who underwent a third 11C-
PIB PET scan demonstrated small changes in cortical PIB retention when scanned at 28 and 
32 months after baseline, + 4% and - 2% respectively.  
 
 
Figure 5-1 11C-PIB PET images in PIB positive MCI with progressive increase in 11C-PIB 
retention ratios  
 
A. 11C-PIB PET at baseline 
B. 11C-PIB PET at 18 months 
C. 11C-PIB at 31 months 
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3. Progression of regional cerebral glucose metabolism  
Five MCI subjects underwent 18F-FDG PET at follow-up. This included the 73 year-old PIB-
positive man who had converted to AD but whose 11C-PIB scan could not be analysed at 
follow-up. At baseline, two MCI subjects demonstrated significant reductions in rCMRGlc 
values. In one subject this was a focal decrease detected in the posterior cingulate cortex 
alone. The other subject had more widespread hypometabolism which included the temporal 
and parietal cortex. During the follow-up period, there was a significant reduction in mean 
rCMRGlc in the anterior and posterior cingulate (p= 0.04) and temporal cortex (p=0.04) of 
the MCI subjects as a group compared to baseline (Figure 5.2). After normalisation to whole 
brain glucose, the anterior cingulate showed a relative reduction of 7%, the posterior 
cingulate 3.4% and the temporal cortex 2.1%. Two MCI subjects had a third 18F-FDG PET 
scan at 25 and 30 months post baseline after which time one demonstrated further reductions 
in metabolic rate over time in all regions while the other showed marginal reductions in the 
striatum only.  
Levels of temporal, anterior cingulate, frontal, and parietal metabolism correlated with 
WRTM for words (Spearman’s rho .894 in all regions; p= 0.041). Low striatal rCMRGlc 
values correlated with a poor performance on Trail making test Part A at follow-up 
(Spearman’s rho -.900; p=.037). 
 
5.3.2. AD 
5.3.2.1. Cognition, PIB binding and glucose metabolism  
1. Cognition: Twelve patients fulfilling NINCDS-ADRDA criteria for AD at baseline were 
serially scanned. Two of the twelve AD subjects were PIB negative at baseline and so were 
excluded from further analysis (see later). Follow-up neuropsychometry was performed in 
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eight subjects. The mean MMSE at follow-up (16.1) of these ten AD subjects was 
significantly lower (p= 0.02) than that at baseline (20.6).  
2. Progression of PIB uptake 
As a group, there was no significant change in 11C-PIB retention in the AD subjects during 
the follow-up period.  However, the changes in 11C-PIB retention were heterogenous as 
illustrated in Figure 5.3, with six patients demonstrating an overall increase in whole brain 
11C-PIB retention during the follow-up and the other four subjects a decrease. There was no 
significant difference between cerebellar SUVs in the subjects at baseline compared to 
follow-up. Two of the 12 patients diagnosed with AD six months prior to their baseline 11C-
PIB PET scan did not demonstrate increased 11C-PIB retention compared to controls in any 
cortical region at baseline. The first subject was a 69 year-old woman who underwent follow-
up 11C-PIB and 18F-FDG PET at 20 and 22 months after the baseline scans, respectively. She 
also went on to have a further 11C-PIB PET scan at 30 months and remained PIB-negative 
(retention ratios in all ROIs < 1.5) with an overall percentage increase in cortical brain PIB 
uptake of only 1.3% over 32 months. 18F-FDG PET scans at both baseline and follow-up 
were normal, although she deteriorated clinically during this time. The second subject was a 
66-year old man, who had three 11C-PIB PET scans, the last being 54 months after baseline 
imaging. PIB retention ratios and his rCMRGlc were normal in all regions at baseline. 
However, by the first follow-up increased 11C-PIB retention was detected in the posterior 
cingulate, frontal, temporal, parietal and occipital cortex compared to the control means. The 
final 11C-PIB PET scan performed 21 months later showed a relative reduction of 1.67% in 
whole brain 11C-PIB retention.  
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Figure 5-2 Changes in rCMRGlc in MCI subjects (n=5) during follow-up 
 
 
 
 
 
 
3. Progression in regional cerebral glucose metabolism 
Four AD subjects had 18F-FDG PET at follow-up. There were reductions in rCMRGlc in all 
patients targeting the anterior cingulate (12.8%), posterior cingulate (17.9%) and the temporal 
cortex (21.4%). 18F-FDG PET scans for one of these AD patients are illustrated in figure 5.4. 
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Figure 5-3 Mean cortical 11C-PIB retention in ten AD subjects 
 
 
 
Figure 5-4 18F-FDG PET in AD patient 
 
A: 18F-FDG PET at baseline   
B: 18F-FDG PET at 22 months 
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5.4. Discussion 
In this 11C-PIB and 18F-FDG PET longitudinal study, over a one to three year follow-up 
period our MCI subjects demonstrated a significant increase in PIB retention with greatest 
uptake being observed in the posterior cingulate, frontal and parietal cortex. During this 
follow-up period there was a parallel significant decrease in rCMRGlc in the MCI subjects, 
three of whom converted clinically to AD.  These subjects all had evidence of increased 11C-
PIB retention at baseline, although the subject with the largest increase in 11C-PIB retention 
did not convert to AD during the follow-up period, retaining a diagnosis of MCI.  
In contrast to our MCI subjects, mean 11C-PIB retention in the AD subjects remained 
unchanged during a mean eighteen month follow-up period, despite a significant decline in 
MMSE and decreases in rCMRGlc. This is consistent with a previous report concerning early 
AD patients (Engler et al. 2006) where no significant change in 11C-PIB retention was found 
for sixteen AD patients when rescanned after two years although rCMRGlc had declined. 
While rCMRGlc in our AD subjects decreased compared to baseline, the decline did not 
reach significance though this is likely to reflect the low power of series as only four AD 
patients underwent follow-up 18F-FDG PET, as discussed earlier. 
The finding of stable PIB retention in our AD subjects, the majority of whom deteriorated 
clinically during follow-up, and increasing 11C-PIB retention in all of our PIB positive MCI 
group irrespective of conversion to AD or not during this period, suggests that amyloid 
deposition occurs ahead of cognitive decline and during isolated recall problems and then 
plateaus as frank dementia ensues. While evidence of amyloid deposition at baseline may 
serve as a sensitive biomarker of subsequent cognitive decline, PIB PET does not provide a 
marker of AD progression.  It is notable however, that changes in 11C-PIB retention in the 
AD subjects were heterogeneous, with some subjects demonstrating an increase in binding 
over time, some remaining stable and others a decrease.  
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Although our results are consistent with findings from other cross-sectional and longitudinal 
studies utilising 11C-PIB and 18F-FDG PET in both MCI and AD patients, a limitation of this 
study is that we did not perform formal partial volume correction of the data. Cerebral 
volume loss leads to an underestimation in PET measurements. The degree of this partial 
volume effect is influenced by structure size with smaller structures such as the hippocampus 
being more susceptible to these effects than larger structures. Accordingly, these effects are 
greater in AD patients in whom atrophy is more marked. Similarly, these partial volume 
effects become a more significant in longitudinal studies, as brain atrophy may progress. This 
would effectively result in an underestimation of changes in PIB retention over time and an 
overestimation of reduction in glucose metabolism. Further long term follow-up in these and 
other MCI and AD patients using formal methods for atrophy correction would allow one to 
address this issue more fully, particularly with regards to whether amyloid deposition truly 
plateaus in AD or continues to rise.  
A significant reduction in reference cerebellar PIB standard uptake values in the MCI group 
at follow-up when compared to baseline was noted, which was not observed in the AD 
patients. This may have led to an overestimation in specific 11C-PIB retention during the 
follow-up period in MCI. However, our results of increasing retention in the MCI patients are 
consistent with a reported series assessing changes in 11C-PIB retention in ageing, MCI and 
AD subjects (Jack et al. 2009). Here, there was also a small trend towards increased PIB 
retention in the AD group during the follow-up period, but as in our study this was non-
significant. Even more recently researchers (Villemagne et al. 2011), also reported small but 
significant increases in PIB retention in MCI patients serially followed up with 11C-PIB PET 
over three years. In this study there was no significant change in cerebellar SUVs over time 
in the larger cohort of 48 MCI patients that were followed up, confirming its suitability as a 
reference region. All 11C-PIB follow-up studies reported to date in AD and MCI patients that 
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have involved serial PIB PET scanning have used a cerebellar reference region (Engler et al. 
2006; Scheinin et al. 2009; Jack et al. 2009). Compared to arterial input methods, a cerebellar 
reference region approach yields robust results with the lowest test- retest variability across 
cortical regions without the need for arterial sampling. However, by using an arterial input 
function, methods such as Logan (Logan 2000) or spectral analysis (Cunningham and Jones 
1993) allow one to directly compute volumes of distribution of 11C-PIB in brain tissue. 
Therefore performing follow-up scans using an arterial input function would be useful to 
quantify whether there are changes in cerebellar PIB binding over time and if so, the direction 
of this change and its significance on measures of regional PIB retention.           
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6. Effects of human monoclonal antibody on amyloid plaque load 
 
6.1. Introduction 
Despite increasing challenges relating to the amyloid cascade hypothesis over recent years, it 
remains clear that Aβ aggregation is an early event in the progression to dementia of 
Alzheimer cases. Therapies have, therefore, remained focused on approaches to reduce Aβ 
load either by inhibiting its formation or increasing its clearance. One such approach is to 
generate antibodies directed against human Aβ through immunisation. This can be done 
actively or antibodies generated elsewhere can be passively infused.    
The first experimental studies involving active immunisation involved transgenic mice 
models of AD (Schenk et al. 1999; Lemere et al. 2000; Janus et al. 2000). These workers 
demonstrated that immunisation with synthetic human Aβ42 reduced Aβ plaque burden and 
improved learning and memory. After the successful completion in 2000 of a phase I safety 
trial of active immunisation in AD subjects with synthetic Aβ42 (Bayer et al. 2005), a phase 
II efficacy study began in 2001. However, the study was halted in 2002 as four patients 
developed meningoencephalitis thought to be secondary to a mediated T-lymphocyte 
response (Gilman et al. 2005). Subsequently, post mortem studies performed on several of 
these vaccinated AD patients showed a dramatic reduction of both diffuse and neuritic 
plaques in neocortical areas but confirmed the presence of both microglial activation and T 
lymphocytes (Ferrer et al. 2004). In order to try and minimise any inflammatory reaction the 
approach of passive administration of monoclonal antibodies to Aβ was next employed in 
AD. The following study, sponsored by Elan pharmaceuticals™, was designed to assess the 
effects of the administration of the monoclonal antibody bapineuzumab, on amyloid plaque 
load in vivo (as evidenced by brain 11C-PIB uptake) in patients with mild to moderate AD.  
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6.2. Methods 
6.2.1. Subjects  
The study design was a multicentre trial, involving four clinical sites, three in the UK and one 
in Finland. UK patients were recruited from specialist cognitive disorders clinics at the 
National Hospital for Neurology and Neurosurgery (London), Victoria Hospital (Swindon) 
and the University Hospital of Turku (Finland). PET scanning for the study took place at 
Imperial College London (Hammersmith campus) and Turku.  
All study subjects met NINCDS- ADRDA criteria for probable AD and were aged 50-80. 
Other inclusion criteria were [1] MMSE score of 18-26 (mild to moderate AD), [2] Rosen 
Modified Hachinski Ischaemic score ≤ 4, [3] on no treatment or a stable dose of 
acetylcholinesterase inhibitor or memantine for at least 120 days prior to screening. Subjects 
were excluded if they had [1] current presence of clinically significant major psychiatric 
disorder e.g. major depressive disorder with Hamilton Psychiatric Rating Scale for 
Depression (HAM-D) score >12, [2] history of neurological disease apart from AD including 
stroke or clinically significant carotid or vertebrobasilar stenosis or plaque, [3] history of 
seizures (excluding childhood febrile convulsions), [4] history of alcohol or drug dependence 
or abuse within the last two years, [5] currently taking antiparkinsonian, anticoagulant, 
anticonvulsive, recent immunosuppressant drugs or cognitive enhancing drugs apart from 
acetylcholinesterase inhibitors or memantine. Subjects were also excluded if their baseline 
11C-PIB (screening PET) failed to detect a raised Aβ loads in at least three brain regions at a 
level previously reported in AD subjects (see later).   
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6.2.2. Trial design and randomisation  
The study was randomised, double-blind, and placebo- controlled. Ethical permission to carry 
out the study was granted by each local ethics committee. Of the 38 patients who underwent 
screening 11C-PIB PET, 28 were deemed eligible to continue in the study (eight excluded 
because they did not have PIB retention ratios of ≥ 1.5 in at least three of the pre-specified 
ROIs). The remaining subjects were then randomised into one of three dosing groups; Group 
A, B and C. Group A received 0.5mg/kg infusions of either immunotherapy or placebo, group 
B received 1 mg/kg and group C, 2 mg/kg. Twenty AD subjects were assigned to receive 
bapineuzumab (7 to 0.5 mg/kg; 7 to 1.0mg/kg and 6 to 2.0 mg/kg) and eight assigned to 
receive placebo (3 to 0.5mg/kg; 3 to 1.0 mg/kg and 2 to 2.0mg/kg). Over the duration of the 
study, each subject received a one hour infusion of the study drug every 13 weeks for up to 
six infusions. The infusions were administered on day 1, weeks 13, 26, 39, 52 and 65. The 
study drug was provided by the hospital pharmacy masked to treatment. Each patient also 
underwent clinical and cognitive assessments with laboratory (haematology) investigations at 
regular intervals and serial volumetric 1.5 T MRI. Over the course of the study patients 
underwent up to four 11C-PIB PET scans, the first of which was a screening PIB PET scan 
prior to the first infusion of study drug. If eligible (i.e. screening PIB retention ratios of ≥ 1.5 
in at least 3 of the pre-specified ROIs), this was followed by PIB PET scans at week 20, week 
45 and week 78. Subjects also underwent 18F-FDG PET at screening and week 78 as part of 
the study. Additionally a subgroup of subjects had CSF examination for measuring Aβ and 
tau concentrations. The duration of each subject’s participation in the study was three years 
(including one year of follow-up after completion of the infusion schedule). The 11C-PIB PET 
aspect of the trial is described below.   
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6.2.2.1. 11C-PIB PET  
Data acquisition: PET scanning was carried out at two separate sites; UK (Cyclotron 
Building Hammersmith Hospital) and Finland (Turku University Hospital). PET was 
performed at both sites using a Siemens ECAT EXACT HR+ tomograph (Siemens 962, 
Knoxville, TN) in three dimensional acquisition mode. After a 10 minute transmission scan 
to measure tissue attenuation of 511 keV γ-radiation, subjects received a target dose of 
370MBq 11C-PIB injected intravenously. Permission to administer 11C-PIB was obtained 
from ARSAC UK and the Finnish National Agency for Medicines. 11C-PIB was 
manufactured and supplied by Hammersmith Imanet, UK and Turku PET Centre, Finland.  
Injection of 11C-PIB was followed by a 90- minute dynamic emission scan where data was 
collected as 32 frames. PET was performed at screening, weeks 20, 45 and 78.  
There was a minimum interval of six weeks between the administration of study drug and 
each 11C-PIB PET scan. To investigate whether bapineuzumab competed with PIB binding, 
assays were performed measuring 3H-PIB binding to synthetic Aβ fibrils and in AD brain 
homogenates in the presence of appropriate concentrations of bapineuzumab, after an 
incubation period of 60 minutes at room temperature.  These assays revealed that 
bapineuzumab did not compete with 3H-PIB binding to synthetic Aβ fibrils or AD brain 
homogenates at concentrations of up to 20 000ng/mL. 
 
Data analysis:  
All PET and MRI scans were sent to a central site (Cyclotron Building Hammersmith 
Hospital), and personally analysed (being blinded to patient identification and treatment 
group). Parametric images of 11C-PIB retention were created as follows; Late (60–90min) 
summation images of tracer uptake created in Matlab were co-registered to each subject’s 
MRI using SPM99 software, allowing co-alignment of PET and MRI images. The co-
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registered PET image was then normalized into MNI stereotaxic space using each 
individual’s MRI as a template. Activity in the cerebellar cortex was sampled using an 
individualized anatomical grey matter atlas created from an in-house probabilistic brain atlas 
(Hammers et al. 2003), allowing the creation of the target region: cerebellum ratio image.  
ROI analysis: For the purposes of this study, 11C-PIB retention was quantified in the anterior 
cingulate, posterior cingulate, frontal, temporal, parietal and occipital cortices. Additionally, 
the overall mean 11C-PIB retention value in these six regions was calculated.   
 
Statistical analysis: 
The following statistical analysis described was performed by K. Gregg, who in his appointed 
role as statistician for the study had access to all relevant study data required for this purpose. 
The 11C-PIB PET retention ratio values were provided personally, having being sent 
electronically via a secure site (I3 statsprobe). Patient demographics and results of 
neuropsychometry tests were also provided to the statistician separately by different 
investigators involved in the study. Analysis of the data was by modified intention to treat; 
that being all randomised subjects who received at least one infusion of the study drug and 
one valid PET scan post baseline screening PET. The primary analysis was a mixed model 
repeated measures analysis comparing week 78 change from baseline in average PIB uptake 
between the bapineuzumab and placebo treated groups. The primary end point was the 
change from screening to week 20, 45, and 78 in 11C-PIB mean retention ratios across the six 
regions of interest (anterior cingulate, posterior cingulate, frontal cortex, temporal cortex, 
parietal and occipital cortex). The explanatory variables in the model were treatment group, 
screening 11C-PIB PET value (as a continuous covariate), baseline MMSE category (high or 
low), visit week, and the interaction between treatment and visit week. The primary analysis 
was a two-sided test of the week 78 least squares mean difference. Additional post-hoc 
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analysis was performed due to differences between groups on baseline assessments including 
mean 11C-PIB PET and neuropsychological test battery scores.  
 
6.3. Results 
Initially, 30 patients were to be enrolled in the study (ratio of bapineuzumab: placebo 7:3). 
However, the sponsor stopped enrolment into the highest dose group (2mg/kg) after reports 
of the development of cerebral vasogenic oedema in some subjects treated with this dose in a 
separate study (Salloway et al. 2009). Hence, 28 patients were enrolled in total after 
successful 11C-PIB screening (ten received 0.5mg/kg, ten received 1mg/kg and eight received 
2mg/kg). Two of these 28 patients, (one bapineuzumab and one placebo) had baseline 11C-
PIB PET only. Therefore, 26 subjects were included in the intention-to treat population; 19 in 
the bapineuzumab group and seven in the placebo. The baseline characteristics of these 
groups are shown in Table 6.1.  
The mean 11C-PIB retention values in the two groups at baseline are shown in table 6.2 and 
individual patient retention values by region are shown in appendix 5. During the course of 
the study, two subjects in the bapineuzumab group withdrew from the study and scans were 
not completed in three. In the placebo group two withdrew from the study and scans were not 
completed in one. At (final) week 78, 15 AD subjects in the bapineuzumab group and five in 
the placebo underwent an 11C-PIB PET scan. 
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Table 6.1 Subject demographics  
 Bapineuzumab Placebo 
Total number 19 7 
Mean age (years±SD) 67.26±8.60 70.0±8.81 
Gender: Women (% total) 8 (42%) 4 (57%) 
Mean duration AD (years±SD) 3.36±2.04 3.40±2.45 
Mean MMSE (±SD) 21.00±2.33 22.29±2.69 
Acetylcholine or memantine use 
(percentage total) 
19 (100%) 7 (100%) 
 
 
Table 6.2 Mean baseline 11C-PIB retention values in AD subjects treated with bapineuzumab 
and placebo.  
PIB retention ratio Bapineuzumab 
(n=19) 
Placebo 
(n=7) 
   Anterior cingulate 2.38±0.27 2.12±0.20 
    Posterior cingulate 2.37±0.24 2.16±0.30 
    Frontal 2.10±0.23 1.88±0.20 
    Temporal 1.83±0.21 1.72±0.22 
    Parietal 2.03±0.23 1.83±0.20 
    Occipital 1.66±0.27 1.60±0.20 
All regional mean 2.06±0.20 1.89±0.19 
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In the pooled bapineuzumab group, there was a reduction in 11C-PIB retention ratio at week 
78 relative to baseline, with the estimated mean PIB retention ratio decreasing by 0.09 (95% 
CI -0.16 to -0.02; p=0.014). The pooled placebo group showed an increase in mean PIB 
retention values at 78 weeks relative to baseline. Here, estimated mean PIB retention ratio 
increased by 0.15 (95% CI 0.02 to 0.28; p=0.022). The estimated mean PIB treatment 
difference between the two groups was -0.24 (95% CI -0.39 to -0.09). When assessed by dose 
group, the difference in mean PIB retention ratio between bapineuzumab and placebo was -
0.24 for the 0.5mg/kg dose group, -0.18 for the 1.0 mg/kg group and -0.29 for the 2.0 mg/kg 
group (Figure 6.1). After adjusting for baseline neuropsychological test score, clinical 
dementia rating sum of boxes score, and mean 11C-PIB retention the estimated mean 11C-PIB 
treatment difference between the two groups was -0.25 (95% CI -0.47 to -0.03) (p=0.025). 
Table 6.3 shows the change from baseline to week 78 in 11C-PIB retention in the 
bapineuzumab and placebo groups, and treatment differences between bapineuzumab and 
placebo subjects. 11C-PIB scans at baseline and at 78 weeks in an AD subject receiving 
bapineuzumab are shown in Figure 6.2.  
Adverse effects were reported in 19 of the 20 bapineuzumab treated patients and in all eight 
of the placebo group and included headache, fatigue, diarrhoea, falls and muscle spasms. 
Although the adverse effects were typically moderate to mild, serious adverse events were 
reported in four of the 20 patients in the bapineuzumab group and three of the eight placebo 
group.  One serious adverse event that was reported in two patients of the bapineuzumab 
group (highest dose cohort) was cerebral vasogenic oedema. These patients were both APOE 
ε4 carriers and had each received one dose of bapineuzumab. 
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Figure 6-1 Observed mean change from baseline over time in 11C-PIB retention in ROIs. 
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Figure 6-2 11C-PIB PET image of bapineuzumab treated subject. 
 
 
6.4. Discussion 
A relative 25% reduction in brain fibrillar amyloid load was detected by 11C-PIB PET in AD 
subjects after receiving passive immunisation for 18 months with antibodies directed against 
Aβ compared to placebo. Proposed mechanisms for the removal of Aβ by antibody include: 
(a) Fcγ receptor mediated phagocytosis of anti-Aβ antibody-Aβ complexes by microglial 
cells (Bard et al. 2000) and (b) a ‘peripheral sink’ mechanism (DeMattos et al. 2001) where 
immunisation resulting in Aβ antibodies peripherally in blood, causes mobilisation of Aβ 
from the brain into the blood. As a separate mechanism, it has also been postulated that Aβ 
antibodies inhibit fibrillar aggregation by specifically targeting Aβ isotopes involved in the 
fibrillation process (McLaurin et al. 2002).     
While there was a significant reduction in mean cortical PIB retention noted in the 
bapineuzumab treatment group compared to at baseline (8.5%), there was a significant 
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increase (16.9%) over the baseline value in the placebo group. Previous longitudinal studies 
assessing PIB changes over time in AD patients have mostly reported no significant change 
over time in PIB retention in AD subjects (Engler et al. 2006; Jack et al. 2009; Scheinin et al. 
2009), as was also observed to be the case in the follow-up of our AD cohort. In this study, 
despite randomization, baseline imbalances were noted between the two groups, with disease 
severity and baseline PIB retention being greater in the bapineuzumab group. However, after 
adjustment for the imbalances, the difference in PIB retention between the two groups 
remained significant. Additionally, significant reductions in the treated group were noted 
when the bapineuzumab treated patients were analysed alone, independently of the placebo 
group. While it is conceivable that this increase in placebo PIB binding may have resulted in 
an overestimation of reduction of mean PIB retention after treatment with bapineuzumab, it is 
not possible to assess whether the increase in PIB binding in those subjects had they not 
received the study drug would have been similar.  
The relationship between amyloid in its various forms (fibrillar, oligomeric and monomeric) 
and cognition is still undetermined and hence one cannot be certain that a reduction in 
fibrillar amyloid will translate to clinical benefit. In this regard, results from previous 
immunisation studies have been mixed. During a phase II trial of active immunisation with 
synthetic Aβ1-42 peptide in patients with mild to moderate AD, no significant differences 
were detected between antibody responders (immunoglobulin G titre ≥1:2,200) and placebo 
groups in the predefined secondary outcome measures of cognitive and disability scores 
including ADAS-Cog, CDR, MMSE and the disability assessment for dementia (DAD). 
However, the z-score analysis of a nine-component neuropsychological test battery showed 
less worsening of performance in antibody responders when compared to placebo. 
Additionally there was an improvement from baseline in the memory domain of the test 
battery, the greatest improvement being associated with higher IgG antibody titres. Although 
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study drug administration for this trial was discontinued because of meningoencephalitis in 
immunised patients, follow up studies of the trial participants have demonstrated reduced 
amyloid burden at autopsy. However, there was no evidence that immunisation had any effect 
on clinical outcome or log term survival (Holmes et al. 2008). Several large scale phase III 
trials (including those with bapineuzumab) are currently underway to further investigate 
clinical efficacy and to further explore the relationship between 11C-PIB retention with 
clinical and other biomarker outcomes.  
Two patients in the highest dose treatment group (2.0 mg/kg) developed cerebral vasogenic 
oedema. 11C-PIB uptake was noted to be severely reduced in the oedematous areas. Both 
cases were asymptomatic in relation to the oedema (detected radiologically), which resolved 
after discontinuing the treatment and both of the patients were APOE ε4 carriers.  Phase III 
bapineuzumab trials are now stratifying patients into APOE ε4 carriers and non-carriers, 
comparing the response to bapineuzumab between the two groups. In these trials, the APOE 
ε4 carriers receive the lowest dose of 0.5 mg/kg only.  
Currently there is no disease modifying treatment for AD. Despite previous problems with 
active immunisation and now reversible vasogenic oedema with passive immunisation at 
higher doses, immunotherapy remains an important treatment strategy, with the potential to 
be used at early stages of disease. PET provides us with the opportunity to monitor the effects 
of this therapy on amyloid load and other biological markers in vivo.  
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7. Conclusions and future directions 
The clinical and histopathological features of the first patient formally diagnosed as having 
AD were described more than 100 years ago. Today, AD is the most common form of 
dementia worldwide, its prevalence being predicted to exceed 100 million globally by the 
year 2050. Over the last ten years a newer concept of mild cognitive impairment has been 
introduced, representing the degree of cognitive impairment between that expected with 
normal ageing and that seen in patients with established dementia including AD. So, not only 
does the continued and increasing need to find effective treatments in those with established 
dementia remain, there is also the need to identify those MCI patients at increased risk of 
progressing to dementia so that they may benefit from any treatment of proven efficacy at as 
early a stage as possible. The aim of this thesis was to establish the role of PET in the early 
identification of disease and monitoring disease progression in those at risk MCI patients, and 
monitoring disease progression and treatment efficacy in those patients with established AD.  
 
Using the PET radiotracers [11C](R)-PK11195 and 11C-PIB the objective of the first study 
was to test the hypotheses that PET can be used to detect inflammation in a significant 
proportion of MCI cases, and to characterise the patterns and relationship of amyloid 
deposition and microglial activation in a group of aMCI subjects in vivo. Fifty percent of 
amnestic MCI subjects had evidence of increased amyloid deposition whereas 38% showed 
increased 11C-PK11195 binding. As a group, the MCI patients with increased PIB retention 
had significantly higher mean levels of cortical PK binding compared to controls. There was 
no correlation between individual levels of amyloid deposition, as measured by 11C-PIB PET, 
and microglial activation, as assessed by 11C-(R)-PK11195 PET. 
One limitation of this study was that APOE genotype status was not available in the MCI 
patients. It has been shown that different APOE alleles influence amyloid load, and so one 
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potential direction for future PET studies is to explore the interaction between APOE 
genotype, amyloid deposition and microglial activation in vivo, particularly in view of the 
lack of correlation found between amyloid deposition and microglial activation. Despite the 
relatively low power of this series, the results of this work provides a rationale for performing 
further larger studies assessing microglial activation in MCI patients and also for following 
up PIB-positive MCI patients with in vivo TSPO markers to enable a better understanding of 
the time course of microglial activation and its significance as a predictor of clinical 
progression to AD. Importantly, such studies would also provide the opportunity to monitor 
the pathophysiological effects of anti-inflammatory agents in vivo. 
 
The objective of the second study was to determine the rates at which aMCI subjects with and 
without an increased amyloid load converted to clinically probable AD during a follow-up 
period of one to three years. The main findings were that 55% of aMCI subjects had 
significantly increased PIB retention at baseline and 48% of MCI subjects (the majority of 
whom were PIB positive), converted to a diagnosis of AD during the follow-up period. All 
those converting to AD at a faster rate had higher PIB retention values compared to slower 
converters.  
Together, these findings suggest that PIB-positive MCI patients are significantly more likely 
to convert to AD than PIB-negative patients. In vivo detection of amyloid deposition in MCI 
with PIB PET even at baseline therefore appears to provide useful prognostic information and 
the question arises whether there would be further changes in amyloid deposition in these 
patients over time and whether this too has any relevance to the clinical conversion to AD. 
This was addressed in the third study. 
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The objective of the third study was to compare changes in both regional cerebral Aβ 
deposition and glucose metabolism (rCMRGlc) in MCI and AD patients longitudinally 
followed for a three year period. During this period of follow-up MCI subjects demonstrated 
a mild but significant increase in 11C-PIB retention with parallel significant decrease in 
rCMRGlc. Three of ten MCI subjects clinically converted to AD during this time. Mean 11C-
PIB retention in the AD subjects remained unchanged during the follow-up period, despite a 
significant decline in MMSE and decreases in rCMRGlc.  
Taken together, these findings suggest that amyloid deposition is an early event on the 
pathway from MCI to dementia, and although evidence of amyloid deposition at baseline 
may serve as a sensitive biomarker of subsequent cognitive decline, PIB PET does not 
provide a marker of AD progression. Rather, clinical progression appears to be more closely 
reflected by continued declines in cerebral glucose metabolism, and as recent studies have 
shown, to other biomarkers of neurodegeneration such as CSF tau and volumetric MRI. This 
viewpoint is consistent with the emerging model of AD where Aβ is thought to initiate the 
pathological cascade but does not directly cause cognitive impairment. In fact it may be 
several years until those asymptomatic subjects with evidence of amyloid deposition develop 
dementia, if at all during life. This has implications for the use of PIB PET as a screening tool 
in the asymptomatic, and one important focus of future research would be to further stratify 
those PIB positive subjects most at risk of developing future AD. 
 
In the final study, the effects of passive immunisation with the humanised anti-Aβ 
monoclonal antibody, bapineuzumab, on amyloid plaque load at 78 weeks was assessed in 
patients with mild to moderate AD. The main finding of this double-blind randomized trial 
was that mild to moderate AD subjects treated with bapineuzumab had reduced cortical 11C-
PIB retention compared to baseline and to placebo treated cases. Although this treatment 
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resulted in a reduction in measurable fibrillar amyloid load, a question remains as to whether 
this can be translated to clinical benefit. Currently, larger clinical trails are underway to 
address this question.   
 
Overall, these studies provide evidence that PET imaging detects the presence of Aβ and 
inflammation in MCI subjects. Through the detection of Aβ, PET serves as a sensitive 
biomarker of future progression to AD although, as neurodegeneration progresses, other PET 
measures (18F-FDG) appear to be more closely related to cognitive decline. Although the 
direct relationship of specific biomarkers to cognitive decline remains unclear, PET allows 
changes in specific biomarkers to be detected and followed in vivo, and with time their 
relevance to ageing and cognition may become certain.  
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Appendix 2  
Individual (ROI) 11C-(R)-PK11195 BP values in 5 MCI subjects with increased 
binding compared to AD and controls   
 Anterior 
Cingulate 
Posterior 
Cingulate 
Frontal Temporal Parietal Whole 
brain 
MCI-2* 0.68† 0.73† 0.62† 0.57† 0.57† 0.60† 
MCI-3* 0.69† 0.60 0.60† 0.40 0.42 0.49 
MCI-10 0.61† 0.70† 0.61† 0.63† 0.62† 0.63† 
MCI-11* 0.78† 0.86† 0.69† 0.71† 0.64† 0.70† 
MCI-14 0.49 0.48 0.49† 0.46 0.52† 0.49 
       
AD (n=15) 0.46±0.16 0.51±0.18 0.43±0.11 0.43±0.08 0.38±0.11 0.43±0.10 
HC (n=10) 0.41±0.09 0.45±0.10 0.35±0.07 0.37±0.07 0.35±0.08 0.37±0.07 
 
* PIB-positive MCI  
AD and HC values = mean ± SD 
†significant increase PK binding (≥ 2SD greater than control mean) 
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Appendix 3 
Spearman’s rho correlations PIB-negative subgroup with MMSE and years duration 
 
 Spearman’s 
rho 
Anterior 
cingulate 
Posterior 
cingulate 
Frontal Temporal Parietal  Whole 
brain 
MMSE Correlation 
coefficient 
-.812* 
 
0.05 
-.493 
 
0.321 
-.522 
 
0.288 
-.812* 
 
0.05 
-.667 
 
0.148 
-.667 
 
0.148 significance 
(2-tailed) 
Years 
duration 
Correlation 
coefficient 
0.00 
 
1.00 
0.088 
 
0.868 
0.088 
 
0.868 
-.088 
 
0.868 
.088 
 
0.868 
 
.088 
 
0.868 significance 
(2-tailed) 
      
   
* Correlation is significant at the 0.05 level (2-tailed). 
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